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Abstract 
The abstract of the thesis of Thomas Andreas Herzinger for the Master of Science 
in Physics presented November 8, 1996. 
Title: Effects of the Cardioprotective Drugs Dexrazoxane and ADR-925 on Doxo-
rubicin Induced Ca2+-Release from the Sarcoplasmic Reticulum 
The sarcoplasmic reticulum is the intramuscular organelle responsible for the reg-
ulation of cytoplasmic calcium levels in muscle. This thesis investigates the effects 
of the cardioprotective drug, dexrazoxane, and its metabolite ADR-925 on doxo-
rubicin induced calcium release from skeletal sarcoplasmic reticulum. Doxorubicin 
is a widely used antineoplastic agent. One of the major side effects of doxorubicin 
usage is chronic cardiotoxicity. Doxorubicin is a potent activator of the calcium 
release mechanism from the SR. The interaction between doxorubicin and the cal-
cium release channel has been proposed as the possible underlying mechanism 
behind cardiotoxicity. A short overview of different hypotheses describing doxo-
rubicin induced cardiotoxicity and proposed mechanisms of cardioprotection by 
dexrazoxane are presented. While dexrazoxane did not appear to affect the cal-
cium permeability of the SR, its metabolite, ADR-925, modulates the ryanodine 
2 
receptor complex. ADR-925 inhibits high affinity ryanodine binding to the ryan-
odine receptor/calcium release channel complex by decreasing the sensitivity of the 
receptor for stimulation by calcium. ADR-925's ability to inhibit doxorubicin stim-
ulated ryanodine binding is independent of the doxorubicin concentration. These 
results demonstrate that ADR-925 directly affects the ryanodine receptor complex 
of the SR by desensitizing the receptor to activation by calcium. Furthermore, 
ADR-925 reduces the inhibitory effect of hydrogen peroxide on the ryanodine re-
ceptor/calcium release channel. This suggests that ADR-925 may protect the SR 
from oxidative effects of free radicals. It has been somewhat controversial whether 
doxorubicin induced cardiotoxicity is due to a specific interaction with the calcium 
release mechanism of SR. The findings presented in this thesis which demonstrate 
that the cardioprotectant ADR-925 interacts directly with the ryanodine receptor 
from SR, further support the hypothesis that the ryanodine receptor is a primary 
target of doxorubicin's action. 
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The Ca2+ Release Channel 
1.1 Introduction 
"The muscle is the instrument of voluntary motion" is the introductory sentence 
of the description of human muscles by the surgeon Ambroise Pare in the 16th 
century. The topic of how this "initial will" ( i, e., an electrical signal), is translated 
into the final mechanical action, the shortening of the muscle, still is not completely 
understood. The process is referred to as "EC Coupling." It is the subject of many 
recent research projects. 
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1.2 Muscle 
There are three different types of muscles. Skeletal muscle is connected to the 
skeletal system and is responsible for its movement. Cardiac muscle, the muscle 
of the heart, is mainly characterized by a slower response time to the electrical 
stimulation and a broader response to hormonal effectors. The third type of mus-
cle is called smooth muscle. It is defined by smaller fibers and a poorly defined 
sarcoplasmic reticulum. The response time of smooth muscle is slower than either 
skeletal or cardiac muscle. In spite of some obvious differences in many respects, 
the mechanism involved in smooth muscle contraction is similar to skeletal and 
cardiac muscle. The following descriptions and the entire thesis will focus strictly 
on skeletal muscle. 
Figure 1 shows the anatomy of human skeletal muscle starting with the entire 
muscle, going down to the molecular level. 
Each muscle contains bundles of fibers a few millimeters in diameter. Each of 
these fascicles are composed of 20 to 40 muscle fibers or myofibers (C). A detailed 
drawing of a muscle fiber is shown in figure 2. Each myofiber is enclosed by a 
plasma membrane, the sarcolemma (S). The myofiber, or muscle cell is multinu-
cleated. It has up to 100 nuclei. 
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Figure 1: Anatomy of human skeletal muscle. A more detailed view of the muscle 
fiber (C) is shown in figure 2. From Bloom and Fawcett [95]. 
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Figure 2: Schematic drawing of a muscle fiber. Mf .. myofibril, L . .. longitudinal 
SR, TC ... terminal cisternae or longitudinal SR, T ... transverse tubule (T-tubule). 
(From (59]) 
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These cells contain individually striated myofibrils, each about 1 µmin diameter 
(figure lD). The myofibrils are the actual contractile mechanism. H. E. Huxley 
showed in 1958 that during contraction two kinds of filament, thick filaments and 
thin filaments, slide past each other so as to produce changes in the length of the 
muscle[45]. In the following years, after advances in electron microscopy, he and 
others were able to determine more details about the mechanism by which muscle 
contracts. In 1965, Huxley was able to determine the composition of the two 
filaments. The thick filament is composed mainly of the protein myosin, while the 
thin filament is primarily the protein actin [46]. A micrograph is shown in figure 
3. The picture shows sharply defined bands. The bands are named after their 
optical properties and have specific functions. The thin actin filament traverses 
the Z-discs (I-band1 ). The A band1 contains both actin and myosin. The length 
of the H region and the I band change during contraction. In a relaxed muscle the 
distance between Z lines (one sarcomere) is such that about half of the length of 
a thin filament and two-thirds of the length of an adjacent thick filament overlap. 
In the region of overlap in a relaxed fiber the array contains twice as many thin 
filaments as thick ones (see figure ll) [46]. 
In 1954 Huxley and Hanson proposed their "sliding filament model" (47]. Ac-
cording to this model the actin filaments are partly withdrawn from the A-band, 
1 I because they are isotropic to polarized light and appear light in electron micrographs. A 
because it is anisotropic 
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Figure 3: Micrograph and corresponding schematic diagram of a longitudinal sec-
tion of a striated muscle from the leg of a frog. Enlargement: about 23,000. 
Reproduced from (46]. 
7 
leaving an observed long lighter central region and stretching the S-filaments in 
the process. Electron micrographs show cross-bridges between the two filaments 
in regular intervals. These bridges are extensions of the myosin filaments and are 
called myosin heads. It is physically impossible for the cross-bridges to stay at-
tached to the same point during muscle contraction. Huxley concluded that the 
cross-bridges generate and sustain the tension developed in the muscle. The cross-
bridges are attached to one site on the filament for part of the contraction. They 
then detach and reattach themselves at a new site further along the actin molecule. 
Huxley further suggested that at each of those sites one ATP molecule is split to 
generate the sliding force. 
Muscle contraction is initiated by an action potential propagating down a neu-
ron. The impulse is transmitted to the muscle membrane at the motor "end plate". 
A wave of depolarization spreads out along the sarcolemma (the membrane sur-
rounding the muscle fiber) [45]. Invaginations of this membrane, called transverse 
tubules, are located at each Z-disc. These tubules transports the signal into the 
cells. Located adjacent to the transverse tubules is the intracellular membrane 
system called the sarcoplasmic reticulum (SR). The SR surrounds the contractile 
elements of the muscle and serves as an intracellular Ca 2+ storage area. 
Calcium release channels from the SR are triggered as a result of the action 
potential that propagates down the nerve. It is the increase of Ca 2+ inside the 
8 
contractile elements of the muscle that allow myosin to bind to actin. The hydrol-
ysis of adenosine triphosphate to adenosine diphosphate and inorganic phospate is 
responsible for the conformational changes of the myosin head during contraction. 
This interaction between myosin and actin results in development of tension and 
length changes and finally muscle contraction. The cycle repeats itself as long as 
Ca 2+ is present. Muscle relaxation is caused by the reabsorption of the released 
Ca2+ into the SR via ATP-driven pumps. 
The linkage between membrane depolarization of the T-tubule and Ca2+ re-
lease from the SR is not fully understood. The functional interaction between the 
control system and the Ca2+-release channels in the SR is refered to as "excita-
tion contraction (EC) coupling". Several different models have been proposed to 
explain this interaction. To understand the mechanism underlying contraction, 
further investigation of the transverse tubules, the SR and the Ca2+ release chan-
nels will be needed. The functionality of the calcium release channel2 and the 
influence of different substances on this mechanism are the subject of studies in 
our laboratory. 
2of white rabbit skeletal muscle sarcoplasmic reticulum 
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1.3 Overview: Ion Channels 
Ion channels are macromolecular pores in cell membranes. The channels provide 
a mechanism for controlling both chemical and electric gradients across the mem-
brane by selective ion exchange. Many types of channels are found within the 
muscle cell. Within one cell, two different channels can transport the same type 
of ion but exhibit different kinetics, conductance and threshold mechanism. Ex-
citation and electrical signaling in the nervous system involve the movement of 
ions through ionic channels. Each channel is responsive to some stimulus: either a 
membrane potential change, a neurotransmitter, or other chemical stimulus, etc. 
The channel's response (called gating) is the opening or closure of the pore. The 
open pore allows some restricted class of small ions to flow passively down their 
electrochemical activity gradients (called selective permeability). This again influ-
ences the membrane potential. The described mechanism provides a regenerative 
and self-propagating electrical signal. In general, channels are named according to 
the specific ion that most favorably passes through them. 
The membrane potential can be calculated from the N ernst equation. This 
equation is derived from the Boltzmann equation of statistical mechanics. The 
10 
Boltzmann equation relates the relative probabilities of finding a particle in state 
1 or in state 2 to the energy difference u2 - u 1 between these 2 states: 
P2 ( U2 - U1) -=exp ----
Pi kT 
k is the Boltzmann's constant, Tis the absolute temperature. For the application 
of this equation, the probabilities are replaced by concentrations, the energies u 
by molar energies U. With U = u/N (N is Avogadro's number) and R = k · N (R 
is the universal gas constant) this becomes 
C2 ( U2 - U1) -=exp -
C1 RT 
Taking the natural logarithms of both sides gives 
C2 
U1 - U2 = RT ln -
C1 
(1) 
U1 - U2 is the molar electrical energy difference due to the membrane potential 
difference E1 - E2 • Considering one mole of an ion S with charge Z 8 , U1 - U2 
becomes z8 F(E1 - E2)· Substituted into (1): 
_ RT ln [Sh 
Es = Ei - E2 - z
8
F [S]i (2) 
This equation is called the N ernst Equation. According to this equation the ionic 
equilibrium potentials vary linearly with the absolute temperature and logarith-
mically with the ionic concentration ratio. 
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Goldman (1943) and Hodgkin and Katz (1949) described the ionic permeability 
and selectivity of membranes in their constant-field theory. The ionic flux across 
the membrane is determined by the concentration gradient and by the electric field 
across the membrane. The Goldman-Hodgkin-Katz (GHK) current equation states 
that the current carried by a specific ion is equal to the permeability for that ion 
multiplied by a nonlinear function of the membrane potential. Goldman, Hodgkin 
and Katz also showed that the resting potential across the membrane (zero net 
current) is related to the concentrations and permeabilities of the ions on the two 
sides of the membrane. If there is only one permeant ion present this equation 
reduces to the Nernst potential. 
Ion channels can be classified in two ways: according to their reactivity or ac-
cording to their kinetics. The former group can be subdivided into two categories: 
Channel activation may occur due to ligand binding ("ligand activated") or due to 
changes in the transmembrane electrical potential ("voltage gated"). Ligand acti-
vation occurs when a chemical reagent binds to an appropriate site on the channel 
and modifies its gating characteristics. Voltage gated channels on the other hand 
are activated by a change in membrane potential. Examples of voltage gated chan-
nels are calcium channels in the brain and calcium, potassium and sodium channels 
in nerve cells. 
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Susuma Hagiwara was one of the first to discover Ca2+ channels which show dif-
ferent kinetic responses to changes in membrane potential (36]. The characteristics 
used to distinguish these channels from starfish eggs are steady-state inactivation, 
activation threshold and selectivity. In 1985 Nowycky et al. proposed names for 
the different types of channels (78]. The L-type channel is found in heart and 
T-tubules and is characterized by long lasting (> 700ms), non-inactivating cur-
rents. They are activated by high voltage and have a high Ba2+ conductance3 of 
25 pS (the Ba2+ conductance is greater than that of Ca2+). In contrast, the T-type 
channel has a relatively small conductance. It shows a transient current, which 
inactivates completely a.fter about 50 ms. The T-type channels are activated by 
low voltages and have small Ba2+ conductance (about 8 pS). These channels are 
found in neurons. Nowycky et al. propose a third type of channel, that is neither 
T nor L type. N-type Ca2+ channels require strongly negative potentials for com-
plete removal of inactivation (unlike L) and strong depolarization for activation 
(unlike T). This channel is intermediate in Ba2+ conductance (~ 13 pS). The N-
type channel is linked to neurotransmitter release. For a review on Ca2+ channel 
types see (69]. 
Since the Ca2+ release channel of the SR is not located in the outer muscle cell 
membrane, it cannot be examined with the patch clamp technique. This method 
3 Unit S: Siemens. IS= 1/fJ 
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is the basis for the categorization each of the three channel-types found in the 
sarcolemma. The Ca 2+ release channel from SR is not classified as a L, T or N 
type channel. 
1.4 T-Tubule 
Transverse (T) tubules are periodic invaginations of the sarcolemma (SL). Al-
though the T tubules are continuous with the SL membrane, the distribution of 
proteins in the membrane is not uniforme [110]. Venosa and Horowicz showed 
in their experiments on frog's sartorius muscle that the density of Na+ pumps is 
substantially greater at the surface than in the tubular membranes (ratio 20:1). 
Narahara et al. also showed that Mg2+-stimulated (Na+ + K+)-ATPase activity 
is 14 times higher in a surface membrane fraction of the SL than in the fraction 
containing the T-tubules [77]. Jaimovich et al. found in TTX4 binding studies that 
the density of voltage-gated Na+ channels in the surface membrane is about four 
times as high as it is in the T-tubules [54]. On the other hand, Ca2+ channels are 
three to four times more common in the T-tubules than in the surface sarcolemma 
(see section 1.5 on page 15). 
It has been shown that even though the sarcolemma and the SR are continuous 
structures, their junctional domains are distinct from their longitudinal domains. 
4Tetrodotoxin 
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Regions in which one terminal cisternae of the SR is adjacent to the sarcolemma 
(SL) are called diades. While structural units which include two junctional SR 
cisternae and one T-tubule segment are referred to as triads. 
Due to the difficult isolation of proteins from the T-tubules, different sources 
refer to approximately 15 to 27 different proteins in T-tubular membrane. The 
proteins of major interest in the T-tubules are the (Na+ + K+)-ATPase and Ca2+ 
channel proteins. Recent studies have focused on a protein of a molecular mass 
of 72 kDa [88]. Chadwick et al. showed that the ryanodine receptor crosslinks 
selectively to this protein [19]. It has been proposed that this protein is in close 
association with the junctional foot protein in the SR. This suggests a possible role 
in EC coupling. 
The junctional foot protein in the sarcoplasmic reticulum (SR) was the first 
structural component of the EC coupling-unit to be described. It connects the SR 
to the sarcolemma/T-tubule while maintaining a gap of about 10 nm between the 
two membrane systems. The foot protein has four large subunits symmetrically 
located around a less dense area. The large size and the characteristic shape of 
the foot proteins facilitated there identification as the ryanodine receptor. 
It is believed that the first step in transverse tubule depolarization/SR calcium 
release is a membrane-sensitive conformational change of a charged voltage sensor 
molecule within the T-tubule membrane referred to as the dihydropyridine receptor 
15 
(DHPR). It has been shown that charge movement at the T-tubule is directly 
coupled to calcium release from the SR. 
1.5 DHP-Receptor 
The dihydrophyridine (DHP) receptor is a slowly activating calcium channel re-
sponsible for most of the charge movement leading to the depolarization of the SL 
prior to muscle contraction. The name originated from its sensitivity to several 
DHPs, found both naturally and synthetically. The DHP receptor is believed to 
play two important roles in the process of muscle contraction [5] [103] [104]. 
The first is its function as a slow Ca2+ channel. Other than the RyR, the DHP 
receptor is not a link in EC coupling signal transmission [35]. The DHP receptor 
is responsible for Ca2+ replenishment. 
As described earlier, the Ca2+ channels in skeletal muscle are mostly found in 
the T-tubules as opposed to the SL [104]. Analysis of DHP binding shows that T-
tubules bind about 33 times more DHP per milligram membrane than does isolated 
sarcolemma (50 pmol/mg as opposed to 1.5 pmol/mg). Also, less than 0.005 U /mg 
Ca2+-ATPase activity5 is detected in SL compared to 2.42 U /mg activity in SR 
[88]. 
5Units: 1 U =transport of 1 µmol Ca2+ per minute 
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Figure 4: Schematic representation of the structure of the DHP receptor. The dark 
shaded area (II-III loop) indicates the critical region for skeletal type EC coupling 
[28] [102]. The four units of homology are displayed linerally and the six putative 
transmembrane segments in each repeat are shown by cylinders. Reproduced from 
[102] 
However, studies by Schwartz et al., in which DHP binding was compared with 
voltage-clamp measurements, showed that less than 5% of the high affinity DHP 
binding sites are functional Ca2+ channels [91]. 
On the other hand, Rios and Brum showed later that low concentrations of a 
DHP are sufficient to inhibit both, SR Ca2+ release and charge movement, which 
is observed just before contraction [86]. They speculate that the DHP-sensitive 
Ca2+channel plays an integral role in EC coupling. Other authors have postulated 
that the DHP receptor is an intramembrane molecule that serves as a voltage 
sensor in the transverse tubules for SR calcium release in skeletal muscle [86] [103] 
[104). 
At sites of peripheral coupling or in the junctional regions of the T-tubules, 
groups of four proteins (called tetrads) were identified with the help of electron 
microscopy (EM). These tetrads are very often found right above the four subunits 
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of the junctional foot protein of the SR. This strongly suggests that feet and tetrads 
interact with each other. There are several lines of evidence that the tetrads are 
composed of four DHP receptors (100]. 
1.6 Sarcoplasmic Reticulum 
The sarcoplasmic reticulum (SR) is a internal membrane system, similar to the en-
doplasmic reticulum of non-muscle cells. As mentioned before and seen in Fig. 2, 
the SR surrounds the myofibrils, i.e., the actin and myosin filaments. The func-
tion of the SR is to control the intracellular Ca 2+ concentration in skeletal and 
cardiac muscle. The main proteins in the SR are the Ca2+ -Mg2+ -ATPase and 
the Ca2+ release channel. The ATPase, a 105 kDa protein, works as a Ca2+ pump 
and is responsible for generating a Ca 2+ gradient across the SR membrane. The 
SR is organized in two distinct and functionally different regions. Meissner used 
isopycnic centrifugation to obtain "light" and "heavy" vesicles from the upper and 
lower ends of a 24% to 45% linear sucrose gradient [70). He showed, that the light 
vesicles were isolated from the longitudinal part of the SR (LSR), that stretches 
along the length of each sarcomere. Ninety percent of the protein found in the 
LSR is the Ca2+ -Mg2+ -ATPase. The heavy SR, also known as the junctional SR 
(JSR) or "terminal cisternae" is found on both sides of the Z-line and appears 
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to be thicker than the longitudinal SR. The heavy SR fraction contains the Ca2+ 
release channel, calsequestrin, and the Ca 2+ pump. 
Calsequestrin is a Ca 2+ binding protein. It binds Ca 2+ with high-capacity and 
moderate affinity. It functions as a Ca2+ storage protein in the lumen of the SR. 
Besides calsequestrin, a set of other intralumenal SR Ca 2+ binding proteins have 
been identified. Calsequestrin is the most important of these proteins; it is the 
only one that is discretely localized to junctional SR [18]. Calsequestrin has been 
found to be associated with the Ca2+ release channel protein complex through 
protein-protein interactions. During the resting phase, most of the calcium in the 
SR diffuses to the terminal cisternae region and binds to calsequestrin. Ikemoto et 
al. proposed an essential role for calsequestrin in EC coupling [49]: They studied 
conformational changes at the calsequestrin protein preceding those of the cal-
cium release channel. They presented data that shows no Ca2+ dissociation from 
casequestrin-free junctional SR by release triggers. After the reassociation of the 
dissociated calsequestrin and the junctional SR, Ca2+ dissociation by triggers was 
restored. They proposed, that Ca 2+ release triggers the production of a signal in 
the foot protein, that is then transmitted to calsequestrin, leading to the disso-
ciation of the bound calcium. In SR vesicles this leads to a transient increase of 
intravesicular Ca 2+ and subsequently to release across the membrane. 
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The junctional foot protein (JFP) is a homotetramer, composed of 4 equal sub-
units and localized in the terminal cisternae region. Takeshima et al. determined 
the molecular weight of each subunit by amino acid sequencing to be Mr ~ 535, 000 
[101]. It remains unclear whether all four subunits are identical. The high molecu-
lar weight protein is a constituent of the SR. The material connecting the JFP and 
the T-tubules has been described as amorphous [31]. Takeshima's sequence anal-
ysis of the subunits suggests that approximately one tenths of the high molecular 
weight protein forms a transmembrane region, whereas the remaining nine tenth 
lie in the junctional gap, which makes up the "foot protein." The plant alkaloid 
ryanodine binds with high affinity to the JFP. [3 H]ryanodine binding experiments 
show approximately two binding sites per subunit [51] (see section 1.7 on page 21). 
The main protein in the longitudinal SR is the Ca2+ pump. The pump trans-
ports Ca2+ actively (ATP-driven) into the SR lumen. The Ca2+ pump is evenly 
distributed throughout the longitudinal SR. It consists of a single polypeptide 
chain of 100 - 150 kDa. For each mole of ATP that gets hydrolyzed, the protein 
transports two moles of Ca2+ into the SR. The pump is capable of lowering the 
cytoplasmic free calcium concentration below 10-s M, and it can establish a Ca 2+ 
gradient of 1,000-fold or greater across the membrane. The concentration of Ca2+ 
pumps in the longitudinal SR is proportional to the rate of relaxation of a specific 
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muscle (i.e. fast twitch muscle fiber has a a higher concentration of Ca2+pumps 
than does slow twitch muscle). 
The junctional SR is the region of the SR associated with T tubules. The 
gap between the SR and the T-tubule is approximately 100-130 A[31] [67]. The 
structure of the T-tubule - SR junction is strong enough to withstand the large 
forces exerted on it during contraction. In striated muscle fibers the alignment of 
SR and T-tubules is maintained during shortening. Nunzi and Franzini-Armstrong 
showed that this is due to radially oriented short filaments, which connect the Z 
disks to the SR and to the T-tubular membranes (79]. 
Ca2+ is released following an action potential. Through a mechanism referred 
to as excitation-contraction (EC) coupling, the SR Ca2+ channel is opened. Due 
to the gradient across the membrane, Ca2+ then diffuses out of the SR within a 
few milliseconds. After the closure of the channel the Ca2+ pump transports the 
Ca2+ back into the SR. The whole cycle of release and uptake can be completed 
in 20 to 50 milliseconds [67]. 
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1. 7 Ryanodine Receptor 
Two classes of Ca2+-release channels are essential for Ca2+ signaling in cells: The 
inositol (1,4,5)-triphosphate (IP3 ) and the ryanodine receptors. The former in-
duces Ca2+ release directly when the receptors are bound to the second messenger 
IP3 • Although some authors have reported IP3 Ca
2+ release from the SR, their 
observations have been disputed. 
Ca2+ release can be mediated by the ryanodine receptor (RyR) Ca2+ release 
channel. This channel is triggered by a surface membrane action potential and/ or 
a change in the concentration of a second messenger, by a mechanism referred 
to in muscle as excitation-contraction (EC) coupling. The classical description of 
the RyR includes Ca2+ and ATP activation, and inhibition by ruthenium red or 
Mg2+. The RyR/Ca2+-release channel has also very high conductance for mono-
and divalent cations, compared to other Ca 2+ channels. Commonly reported values 
for the conductance of the RyR are ~ 110 pS for Ca2+, ~ 380 pS for Cs+, and 
~ 400 pS for Na+ [96] [97]. 
The protein structure that is now known as the Ry R/ Ca 2+ release channel is 
located where the junctional SR comes in close contact with the T-tubules. These 
structures were formerly known as "feet" (see section 1.4 on page 13), but were 
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renamed because of their Ca2+ channel activity and their ability to bind the plant 
alkaloid ryanodine with high affinity and specificity. 
Immunolabeling studies of the SR indicate that some (18% to 21%) RyRs (or 
their subunits) are present in the longitudinal SR [26]. Franzini-Armstrong and 
Jorgensen [33] speculate that these might be molecules in transit from their site of 
synthesis to their final foot junction location. These molecules can probably not 
be resolved in electron microscopy studies, because the Ry Rs do not form arrays 
in this region. Further studies showed that these proteins do not significantly 
contribute to the calcium release and therefore EC coupling [44]. 
Using the zwitterionic detergent CHAPS and high ionic strength (1.0 M NaCl), 
the membrane bound RyR of a variety of tissues6 was solubilized and purified as 
a 30 S protein complex. SDS gel electrophoresis suggests that the purified RyR 
of mammalian skeletal and cardiac muscle contain a single major high molecular 
weight polypeptide with a calculated Mr of ~ 560, 000 Da, as determined by 
cloning and sequencing of the complementary DNA (see [76] for cardiac and [101] 
for skeletal muscle DNA expression) of the mammalian skeletal and cardiac muscle 
RyR isoforms (for reference see [8], [50], [51] and [60]). Hydropathy plots suggest 
that the Mr ~ 560, 000 polypeptides consist of two major structural regions: a 
carboxy-terminal pore region, and a large extramembrane region. The former is 
6For reference on rabbit skeletal muscle that was used in this study, see [48], [60] and [97] 
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thought to consist of as few as four [101] and as many as ten or possibly twelve 
[113] putative transmembrane segments. 
Electron microscopy studies showed that the purified 30 S Ry Rs of mammalian 
skeletal, cardiac muscle and brain have an overall morphology identical to the 
protein bridges (feet, see section 1.6 on page 18), that span the gap between the 
T-tubules and the SR [33]. The four leaf clover-like ( quatrefoil) appearance of 
negative-stained samples, the apparent sedimentation coefficient of 30 S [60], and 
cross-linking and scanning transmission electron microscopy studies have demon-
strated a tetrameric assembly of the high molecular weight subunits of the CHAPS-
purified skeletal RyR [74). Lai et al. showed that the complete tetramer is neces-
sary for ryanodine binding and channel activity [60]. 
Studies of averaged images of negatively stained [115] and frozen hydrated 
[84] specimens showed a more detailed view of the structure of the rabbit skeletal 
muscle RyR. These images have a resolutions of~ 3 nm. They indicate an overall 
dimension of 27 x 27 x 14 nm for the skeletal Ry R. They further suggest the pres-
ence of an ion-conducting structure comprised of a central (membrane-spanning) 
channel that branches into four radial channels in the cytoplasmic (foot) region of 
the complex. 
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Figure 5: Computer generated sur-
face of the three-dimensionally re-
constructed junctional channel com-
plex. Upper image: stereo pairs of 
the reconstruction in various orien-
ations related by rotation about a 
vertical axis. Lower image: Two 
complementary halves of the recon-
struction after slicing it in half to 
reveal internal structural features. 
Left picture: View from inside the 
channel towards the T-tubule sur-
face, right picture: view from the 
same spot to the other direction. 
Abbreviations: BP Base platform, 
PL peripheral lobes, PV peripheral 
vestibules, CC central channel, RC 
radial channels. The scale bar in-
dicates 10 nm. Reproduced from 
[115]. 
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1.8 EC Coupling 
The functional interaction between components of the calcium release mechanism 
and the control system is called excitation-contraction coupling (EC coupling). 
Events in this process include depolarization of the surface membrane, the detec-
tion of this depolarization by voltage sensors and the resultant release of calcium 
from the SR. In vertebrate skeletal muscle the functional components reside in the 
junctional membrane of the sarcoplasmic reticulum (SR) and the immediately ad-
jacent transverse tubules of the sarcolemma membrane. After the depolarization 
of the sarcolemma, the transverse tubule system carries the signal radially into the 
muscle fibers for nearly synchronous initiation of SR calcium release throughout 
the fiber volume. The T-tubules establish specialized junctions (T-SR junctions, 
triads, or diads) with the SR (see section 1.4 on page 14); these junctions are 
involved in the transmission of excitation stimuli. The depolarization of the sar-
colemma triggers a charge movement in these structures, which initiates a series of 
events that culminates in the release of stored calcium from the SR. Very little is 
known about the structure and function of the systems participating. Three ma-
jor mechanisms for the actual signal transmission between T-tubules and SR have 
been considered. These are mechanical coupling, electrical coupling and chemical 
coupling. 
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1.8.1 Mechanical Coupling 
The earliest proposal for the EC coupling mechanism was a direct mechanical in-
teraction between the T-tubule voltage sensor and the SR calcium release channel 
[20]. In this model the T-tubule voltage sensor was thought to block the release 
channel directly ("plunger model"). The plunger was removed by a voltage depen-
dent movement of the sensor during TT depolarization. Upon the discovery of the 
high molecular weight ryanodine receptor (Ry R), this model was modified in such a 
way that indicated that the interaction was now occurring at a domain of the Ry R 
which was distinct from the Ca2+ release domain. The DHP receptor, as viewed 
in the mechanical model, could exert an inhibitory effect on the RyR/Ca2+ release 
channel, while in its resting state. This would be possible via a voltage dependent 
conformational change of the DHP receptor during T-tubule depolarization. 
Chandler's model gained new credibility when Block et al. presented structural 
evidence for a mechanical interaction between the junctional foot protein and the 
a 1 subunit of the DHP receptor [12]. Block showed evidence for the presence of a 
large junctional complex spanning the two junctional membranes and intervening 
gap. Utilizing this complex, the DHP receptor could directly stimulate Ca2+ release 
from the SR. 
Franzini-Armstrong, however, showed an alternate disposition of tetrads in 
some muscles, i.e., the distance between tetrads were twice the distance between 
27 
adjacent feet (32]. This resulted in tetrads being associated with alternate feet. 
A variable ratio of tetrads to feet would greatly weaken the direct mechanical 
coupling hypothesis. 
1.8.2 Electrical Coupling 
The idea of an electrical coupling mechanism may seem reasonable, because muscle 
contraction is initiated by an electrical impulse. A direct current flow between the 
T-tubules and the SR would cause a depolarization of the SR and then induce Ca2+ 
release. Eisenberg showed, however, that no sign of depolarization was apparent 
in high impedance measurements of muscle cells [27]. 
Mathias et al. proposed an influx current carried by ions as the coupling mech-
anism (68]. Meissner showed, however, that the sarcoplasmic reticulum membrane 
is uniquely permeable to various biologically relevant monovalent ions [71]. The 
only significant gradient over the membrane is the one of Ca 2+. Stefani [99] and 
Eisenberg [27] demonstrated that none of these Ca 2+ currents plays a direct role 
in EC coupling. In addition, single channel measurements in lipid bilayers showed 
very little voltage dependence for the Ca2+ release channel. 
Schneider and Chandler proposed an electromechanical mechanism of EC cou-
pling [89]. They observed charge movement across the T-tubules membrane. The 
range of membrane potentials, in which charge movement occurs is the range in 
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which many of the electrical and mechanical properties of muscle are regulated. 
Schneider and Chandler suggested a physical movement of charged particles that 
could represent a molecular trigger. 
1.8.3 Chemical Coupling 
Several chemical compounds are capable of opening and closing the Ca 2+ release 
channel. Many of them are not physiologically present, and therefore have no 
influence of the EC coupling process. Ca2+ is the chemical messenger in cardiac 
SR that triggers Ca2+ release ("Ca2+ induced Ca2+ release") [108). In skeletal 
muscle, this mechanism is not applicable. Contraction is possible, even without 
any extracellular calcium [5] (86). In addition, the DHP receptor would not be able 
to supply the Ca2+ that could trigger Ca2+ release from the SR. The function of 
the DHP receptor is slower and longer lasting than the activation of contraction. 
Finally, the blockade of the Ca2+ release ability of the DHP receptor by Cd2+ was 
shown not to prevent EC coupling [ 6). 
Other chemical coupling mechanisms were proposed and include activation by 
the second messenger IP3 , and gating by sulfbydryl oxidation. These are discussed 
in the following sections. 
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Phosphorylation by Inositol 1,4,5-triphosphat (IP3 ) 
Inositol 1,4,5-trisphospate (IP3 ) has been shown to mobilize Ca
2+ from intracellular 
stores, in the endoplasmic reticulum, in a variety of cell types [11]. Volpe et al. 
showed that IP3 also releases Ca
2+ from isolated purified sarcoplasmic reticulum 
[114]. Ruthenium red, a blocker of terminal cisternae Ca2+ channels antagonized 
the release. Application of IP3 to skinned fibers also results in force production. In 
their article, Volpe et al. proposed a possible model for EC coupling in which after 
T-tubule depolarization IP3 is produced at the myoplasmic leaflet of the T-tubule 
membrane and released into the triadic junction. IP3 sensitive Ca
2+ channels, 
localized in the junctional SR, open and free Ca2+ increases. Vergara presented 
further evidence for IP3 release in experiments where he electrically stimulated 
muscles fibers [111]. 
One problematic aspect of the IP3 hypothesis is that the sensitivity of skinned 
fibers to extrinsic IP3 increases when the T-tubular membranes are depolarized 
[25]. This indicates that the putative receptor "knows" the state of the voltage 
sensor before receiving the IP3 message, thus suggesting the existence of another 
pathway of communication. 
Another problem with this hypothesis is that IP3 does not cause Ca2+release 
from SR vesicles or modify ryanodine binding, one of the most common probes for 







Figure 6: Model of the Ca 2+ re-
lease protein gated by SH oxidation 
and reduction of three endogenous 
SH groups. Reproduced from [2]. 
Abramson and Salama have proposed a model in which Ca2+ channel gating is 
controlled by the oxidation state of critical sulfhydryl groups on the Ca 2+ release 
channel [3] (see Fig. 6). The oxidation of two sulfhydryl groups to a disul-
fide linkage opens the channel while the reduction of this linkage closes it. The 
sulfhydryl groups can also bind heavy metals and release Ca2+ [4]. The stimulation 
of Ca2+ release by heavy metals correlates strongly with the affinity of those metal 
ions for SH containing agents. 
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Reactive disulfide reagents, that specifically react with SH groups, also stim-
ulate Ca2+ release from SR vesicles and induce contraction in chemically skinned 
muscle fibers. Zaidi et al. showed that reducing agents reverse this effect and thus 
favor Ca2+ uptake [119]. 
Liu et al. used the :fluorogenic sulfhydryl probe CPM7 to characterize the 
functional role and location of these thiol groups in skeletal and cardiac junctional 
SR (62]. They found that the kinetics of the formation of :fluorescent CPM adducts 
with junctional membrane are strongly dependent on the presence of physiological 
and pharmacological modulators that are bound to the RyR. Treatment with RyR 
agonists (e.g., micromolar Ca2+ or nanomolar ryanodine), promote a slow SR thiol-
CPM reaction. In the presence of Ca2+ channel antagonists (e.g. millimolar Ca2+, 
millimolar Mg2+, or micromolar ryanodine) however, CPM rapidly forms adducts 
with a single class of highly reactive (hyperreactive) SR thiols. The apparent rate 
constants for the reaction with the agonists and antagonists are k = 0.0021 s-1 
and k = 0.025 s-1 , respectively. 
Gel electrophoresis of CPM-labeled SR protein and Western plot analyses with 
antitriadin and antiryanodine antibodies show that the hyperreactive thiols la-
beled by CPM under conditions favoring channel closure are localized at the RyR 
protomer and triadin. 
7 7-diethy lamino-3-( 4 '-maleimidy lpheny I )-4-methylcoumarin 
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These results reveal that the Ry R and triadin have a small number of highly re-
active cysteine residues that selectively conjugate with CPM when channel closure 
is favored. Liu et al. suggest that either the redox state of the sulfhydryl group 
controls the state of the channel, or the accessibility of the thiols is determined by 
the functional state of the channel [62]. Other experiments support the first inter-
pretation. Modification of the thiols with nanomolar CPM inhibited Ca2+ induced 
Ca2+ release, and the gating activity of single channels in bilayer experiments [62]. 
The data mentioned above strongly suggests the presence of hyperreacti ve 
residues on the RyR and triadin, and describes their functional role in the gating of 
the calcium release channel. The redox-sensitivity of the thiol controlled channels 
makes them an important target for physiologically relevant oxidizing agents (see 
section 2.1.1 ). 
Even though sulfhydryl oxidation seems to be an important link in EC cou-
pling, the physiologically relevant trigger mechanism for this model has still to be 
discovered. 
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1.9 Mechanisms of Ca2+ Release from Sar-
coplasmic Reticulum 
Ca 2+ effi.ux from SR occurs by several mechanisms which may be interrelated. 
These mechanisms differ in sensitivity to physiological effectors or pharmacological 
agents as well as in their relevance to EC coupling. These mechanisms also include 
channel independent Ca2+ release such as Ca2+ leakage through SR membrane 
as well as reversal function of the Ca2+ pump. They are of minor interest for 
ryanodine receptor studies and will not be discussed further. 
1.9.1 Modulators of the SR Ca2+ Release Channel 
In the absence of other regulatory ligands such as Mg2+ and ATP, a bell-shaped 
Ca 2+ dependence curve for Ca 2+ efflux from SR vesicles has been obtained (for 
a review see [22]). The maximum Ca2+ efflux was observed at micromolar Ca2+ 
concentrations. The Ca2+ efflux rate decreased at both, higher (10-3 M) and lower 
(10-9 M) Ca2+ concentrations. This suggests that the Ca2+ release channel pos-
sesses high-affinity activating and low-affinity inhibitory Ca2+ binding sites. 
In contrast to Ca2+, Mg2+ inhibits SR Ca2+ release. This happens by multiple 
mechanisms: a) competition with Ca2+ for the Ca2+ activation sites, b) binding 
to the low-affinity Ca 2+ inhibitory sites, and c) blocking of the channel (i.e., Mg2+ 
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binds to a site near the conduction pathway [73]). The effects of Mg2+ are physio-
logically relevant, because the free Mg2+ concentration in muscle cells is between 
0.6 mM and 1.0 mM. 
Adenine nucleotides have been shown to be potent Ca 2+ release stimulators. 
The concentrations of ATP, the primary energy source in the cell, have been es-
timated to be as high as 5 mM in skeletal muscle. Adenine nucleotides (in the 
millimolar concentration range) enhance Ca2+-induced Ca2+ release [72]. They 
also promote heavy metal induced Ca2+ release [4], sulfhydryl oxidation induced 
Ca2+ release [107] and ryanodine stimulated Ca2+ release [82]. Various other ade-
nine nucleotides besides ATP (e.g., AMP-PCP, cAMP, ADP, adenosine or AMP) 
potentiate Ca2+ release [82]. Since AMP-PCP is a non-hydrolyzable ATP ana-
logue and is also a potent activator of Ca2+ release, this suggests that activation 
occurs because of binding to an effector site rather than covalent modification of 
the channel protein via a phosphorylation reaction. It is likely that MgATP, rather 
than free ATP, is a major physiological regulator of the RyR ion channel because 
most of the nucleotide in cells is complexed with Mg2+. The addition of Mg2+ 
and adenine nucleotide at concentrations approximating those in muscle ( 5 mM 
adenine nucleotide, 0.7 mM free Mg2+) was strongly stimulatory at µM concentra-
tions of Ca2+ and indicated the existence of a regulatory site that, upon binding 
of MgATP, rendered the channel more sensitive to activation in a narrow Ca2+ 
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concentration range [73]. In the cell adenine nucleotide and Mg2+ concentrations 
do not undergo rapid changes and so it is unlikely that these channel modulators 
play an important role in EC coupling. 
Caffeine is known to activate muscle fiber contraction and to stimulate Ca2+ 
release from SR vesicles. [3H]ryanodine binding assays showed a decrease of the 
threshold for Ca2+ activation as well as an increase of maximum binding in the 
presence of caffeine [82]. 
Ryanodine is known to show a biphasic behavior. Nanomolar ryanodine (5 to 
40 nM) activates the channel. Altered channel gating kinetics with low nanomo-
lar ryanodine were shown to be fully reversible. This behavior is used in the 
[3H]ryanodine binding experiments that are described later (see section 3.2.2 on 
page 64). Micromolar concentrations (2:: 70 µM) of ryanodine inhibit channel gat-
ing, whereas concentrations > 200 µM cause complete closure of the channel [16]. 
Ruthenium Red, a polycationic dye, has been shown to inhibit Ca2+ release 
from isolated SR vesicles [73] [107]. The inhibitor is effective at concentrations 
< 5 µM. The inhibition is irreversible. 
Anthraquinones, like doxorubicin, have been described to directly interact with 
the SR Ca2+ release mechanism [1] [120). Doxorubicin induced Ca2+ release from 
skeletal [120] and cardiac [57] SR vesicles. A detailed description of this effect is 








Calcium 0.1-100 µM Calcium > 1 mM 
Adenine Nucleotides 1-5 mM Magnesium 0.5-5 mM 
Caffeine 1-100 mM Ruthenium Red 0.001-20 µM 
Ryanodine 5-40 nM Ryanodine > 70 µM 
Doxorubicin 1-300 µM CPM 10-100 nM 
Table 1: Modulators of the Ca 2+ release channel of the sarcoplasmic reticulum. 
Data from (22] 
An overview of some modulators of the SR Ca2+ release channel is shown in 
Table 1. 
Chapter 2 
Doxorubicin, Dexrazoxane and 
ADR-925 
2.1 Doxorubicin 
The antitumor drug doxorubicin (or Adriamycin) belongs to the class of 
anthracyclines1. Anthracyclines engulf the widest spectrum of activity in hu-
man cancers. The chemical structure of some anthracyclines is shown in Fig. 7. 
Doxorubicin in fact was among the first two of these anthracyclines to be developed 
in the 1960s. The development of doxorubicin was the result of an effort of finding 
analogs of daunorubicin, which was the first known anthracycline. Clinical trials 
1 The name anthracycline is based on the presence of an anthraquinone chromophore and a 























Figure 7: Structure of the antitumor 
anthraquinones. Reproduced from 
(66]. 
of daunorubicin showed that this drug had high activity for acute leukemia (this 
cancer is still the only one for which it is effective), but produced fatal cardiac 
toxicity. Doxorubicin differs from daunorubicin only by a single hydroxyl group 
(see Fig. 7) and was shown to have greater activity against some murine cancers 
and a better therapeutic index than daunorubicin. Doxorubicin remains the anti-
tumor drug with the widest spectrum of antitumor activity, but like daunorubicin, 
its usage is limited by its cumulative cardiotoxicity, which prohibits treatment for 
more than 9 months at usual doses (maximum cumulative dose: ~ 550mg/m2 ). 




The use of doxorubicin is often limited because of its dose-dependent cardiotoxicity 
[83]. Systolic and diastolic dysfunction can occur after either acute or chronic 
exposure to anthracyclines. The magnitude of the dysfunction depends on the 
duration of exposure to anthracyclines. 
Doxorubicin has a number of effects on the cell. The most obvious damage 
is the degeneration of myofibrils. Microscopic lesions appear in the sarcoplasmic 
reticulum and mitochondria after just the first few hours2 after injection of the 
drug. The lesions progress in severity over the next couple of days. The SR 
degenerates, the mitochondria swell and finally disrupt [61]. Studies on isolated 
mitochondria showed that doxorubicin disables the mitochondria to sequester cal-
cium. Doxorubicin was also shown to decrease ATP and creatine phosphate levels 
in rat heart preparations by 25%. 
Micromolar3 doses of doxorubicin trigger complete calcium release from cardiac 
[57] and skeletal [120] SR. The effects of doxorubicin on the SR are discussed in 
section 2.2. Anthracyclines can also stimulate calcium influx through slow channels 
in the sarcolemma. Very low concentrations of doxorubicin ( < lµM) can enhance 
2 Research done on mice 
3 IC50 for skeletal muscle: 0.5 µM, for cardiac muscle: 5 µM. 
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calcium influx by activating a cAMP4-dependent protein kinase5 that phosphory-
lates channel proteins. Anthracyclines may also increase cytoplasmic calcium by 
the inhibition of Ca2+ -ATPase of the sarcolemma. 
Despite the knowledge of these subcellular effects of anthracyclines, the mech-
anism of the cardiotoxicity is still elusive. Several hypotheses to explain cardiotox-
icity have been proposed, and are discussed in the following sections. 
Free Radical Hypothesis 
Reports from as early as the mid 1970s indicate that quinone-containing anticancer 
drugs produce free radicals in NADPH-microsome systems. The nicotinamide din-
ucleotides, to which NADP6 belongs, represent a class of high-energy compounds. 
N ADP is a coenzyme for a large number of dehydrogenase enzymes. It acts as an 
agent in the transfer of hydrogen atoms in oxidation-reduction reactions. N ADPH 
symbolizes the reduced species of NADP. In the presence of an oxidized substrate 
and an appropriate reductase, NADPH is oxidized and acts as an electron (or 
hydrogen) donor. In the case of doxorubicin, this quinone can be reduced to the 
free radical semiquinone form (step 1 in Fig. 8). Other possible mechanisms of 
the quinone reduction, such as cytochrome P-450 reductase, NADH and NADH 
4 Adenosine-3' ,5 '-cyclic monophosphate, a second messenger nucleotide 
5Kinase: Reaction, where ATP acts as a donor of phosphate 
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Figure 8: Proposed free radical hypothesis for doxorubicin-induced myocardial 
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Figure 9: Enzymatic reactions in which reduction· of doxorubicin leads to the 
formation of oxygen free radicals. Doxorubicin, in the quinone form, accepts an 
electron from various possible donor reactions. This yields the semiquinone free 
radical. As the semiquinone cycles to the quinone, it transfers an electron to 
molecular oxygen, yielding superoxide anions. The superoxide anion can either 
initiate formation of lipid peroxides or be dismutated to hydrogen peroxide. Both 
products decompose to oxygen-centered free radicals. Reproduced from [81]. 
dehydrogenase, or the xanthine/xanthine oxidase pathway, are shown in Fig. 9. 
The semiquinone free radical can be further oxidized to its original quinone form 
by 0 2 (Fig. 8, 2), creating superoxide anions. The superoxide anion may initiate 
lipid peroxidation (3), or be dismutated via superoxide dismutase to hydrogen per-
oxide ( 4a). Su peroxide radicals are also converted back to oxygen through ferric 
ion reduction to the ferrous iron ( 4b ). Because of the low catalase activity of the 
heart ( 5a) and the destruction of glutathione peroxidase ( 5b) by doxorubicin, the 
natural defense mechanisms for disposing H20 2 are severely impaired. Together 
with reduced iron, H20 2 is converted to highly toxic hydroxy free radicals. These 
radicals cause severe lipid peroxidation and can also crosslink sulfhydryl groups 
A. 
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Figure 10: N onenzymatic mechanism for free radical generation by doxorubicin. 
Doxorubicin complexes with ferric iron (A). The doxorubicin-iron(III) complex 
undergoes redox cycling (B, C) to form superoxide anions and peroxides. Electron 
donor is either reduced glutathione (B, [121]) or doxorubicin (C, D). Reproduced 
from [81]. 
of the calcium release channel (8a,b ), causing excessive flux of calcium into the 
cytoplasm. All three, superoxide anions, lipid peroxides and hydrogen peroxide 
can generate free radicals which damage membra.p.es and cause myocardial injury. 
Additional processes for the production of free radicals have been suggested. 
Besides the previously mentioned "enzymatic" mechanisms, some "nonenzymatic" 
reactions are possible. Nonenzymatic mechanisms include reactions of anthracy-
dine and iron (Fig. 10). Only very little free iron is available in myocytes, but 
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Figure 11: Illustration sug-
gesting that doxorubicin, by 
oxidizing sulfhydryl groups on 
calcium release channels of 
sarcoplasmic reticulum, pro-
motes release of calcium into 
the cytoplasm. Reproduced 
from [81] as a modification of 
Fig. 6. 
Demant showed that doxorubicin can abstract iron from ferritin (24], i.e., bound 
iron can contribute to free radical production as well. 
The immediate effect of free radicals on the SR is easily described with the 
sulfhydryl oxidation model of calcium release (see section 1.8.3, page 30). Accord-
ing to this model calcium release involves redox cycling of sulfhydryl groups at the 
terminal cisternae. Oxidation by peroxides or by the quinone/ semiquinone redox 
cycle directly (Fig. 11 ), promote rapid release of calcium from the SR (Fig. 8, 
(8a,b)) (2). In addition to the effects on the release channel itself, free radicals can 
also impair calcium sequestration by the SR. Both effects combined can lead to an 
impaired contractility (a decreased supply of calcium) and an impaired relaxation 
(an increased calcium in myofibrils). Besides the effects on the SR, free radicals 
can also injure mitochondria. 
Yet many limitations of the free radical hypothesis were shown. Vitamin E, 
a lipid-soluble free radical scavenger, did not reduce lipoperoxidative damage, as 
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it was predicted from the free radical hypothesis [109]. Furthermore vitamin E 
deficiency did not enhance doxorubicin cardiotoxicity. Another problem of the free 
radical hypothesis is the fact that the heart is a poor free radical generator. Oxygen 
consumption (a measure of lipid peroxidation) was shown to be 23 fold greater in 
liver than in cardiac microsomes. In addition Jackson et al. could not show any 
lipid peroxidation in rabbit, even with large doses of doxorubicin. Jackson also 
emphasizes that the glutathione peroxidase activity was not altered significantly 
[53]. Thus, in multiple cases there is no evidence of oxidative stress or free radical 
production at doxorubicin doses that are known to cause cardiac injury. From a 
comparison of doxorubicin and daunorubicin, another anthraquinone that is more 
cardiotoxic than doxorubicin but less potent ( ~ 1/6) to produce free radicals, 
it was shown that free radicals cannot be the only mechanism responsible for 
cardiotoxicity. 
These limitations suggest that free radical generation in the heart may con-
tribute to doxorubicin cardiotoxicity, but that other factors probably play a more 
important role in the origination and development of the myocardial damage. 
Calcium Overload Hypothesis 
According to the calcium overload hypothesis, anthracyclines increase intracellu-
lar calcium dramatically. Changes in the calcium equilibrium result in disrupted 
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excitation-contraction coupling and mitochondrial dysfunction [80]. More recent 
studies suggest that calcium accumulation is a manifestation rather than a cause 
of anthracycline cardiotoxicity [55]. Jensen et al. provide evidence that calcium 
deficiency occurs rather than overload (55]. In addition, the calcium overload hy-
pothesis fails to provide mechanisms of injury or specific injurious agents. 
Histamine Hypothesis 
Histamine has been suggested as a mediator of anthracycline cardiotoxicity. His-
tamine is the decarboxylation product of the aromatic amino acid histidine. Exces-
sive production of histamine occurs during hypersensitive allergic reactions. Bris-
tow et al. reported doxorubicin stimulated histamine release from isolated rabbit 
heart preparations [15]. Prior exposure of isolated hearts to cromolyn sodium, a 
compound that completely prevents histamine release from 5 µg/ml doxorubicin, 
produced significant protection against doxorubicin mediated cardiotoxocity [15]. 
It is known that free radicals can stimulate histamine release. Free radicals pro-
duced by the mechanism described by the free radical hypothesis could therefore be 
the origin of the observed histamine release. This concept is supported by studies 
of Klugmann et al., which show that the free radical scavenger N-acetylcysteine 
inhibits anthracycline induced histamine release [58]. 
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How histamine causes cardiotoxicity remains unclear. At present, there is little 
evidence that exposure to histamine causes cardiotoxic effects similar to anthracy-
clines [81 J. 
Anthracycline Metabolite Hypothesis 
A rather fundamental question in anthracycline cardiotoxicity is whether the an-
thracycline itself or a metabolite of it is the cardiotoxic agent. There is increasing 
evidence to support the role of doxorubicinol (a C-13 alcohol metabolite of doxo-
rubicin) in the cardiotoxicity of doxorubicin therapy. Doxorubicinol is produced 
inside the myocytes via anthracycline reductase. 
The time-delayed cardiotoxicity of doxorubicin promotes the hypothesis that 
doxorubicinol is the actual cardiotoxic agent. Doxorubicin, in heart, has a half-life 
of approximately 1-3 days. Doxorubicinol on the other hand has been observed to 
accumulate in cardiac tissue [23]. 
Doxorubicinol can impact cardiac function by inhibition of specific ion-
dependent pumps of the SR. Examples are the Ca2+-stimulated ATPase in the 
SR, the Na+ -K+-ATPase of cardiac sarcolemma and the Mg2+-dependent ATPase 
in mitochondria [14]. Why doxorubicinol inhibits those enzymes, and why it is 
much more potent in doing that than doxorubicin is unclear. But according to the 
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kinetics, it is probably unrelated to free radical production. Doxorubicinol inhibits 
the enzyme activities more rapidly than free radicals can be generated. 
The inhibition of the ion transport systems could explain the potency of dox-
orubicinol, and therefore doxorubicin, as a cardiotoxin. Doxorubicinol could block 
calcium uptake into the SR. The result would impair both systolic and diastolic 
functions of the muscle. 
Summary 
Anthracyclines impair cardiac function, presumably by disturbing calcium home-
ostasis. Several hypotheses have been proposed, but none of them describes the 
cardiotoxicity adequately. The free radical hypothesis is popular, but has serious 
limitations. The metabolite hypothesis shows doxorubicinol to be a potent sub-
stance that inhibits systolic and diastolic functions and explains the time-course of 
the observed cardio desease. However, doxorubicin is known to have severe effects 
on subcellular prosseses involving calcium metabolism of the myocyte and does 
play an important role in cardiotoxicity as well. The investigations in this study 
will solely concentrate on the effects of doxorubicin; doxorubicinols impacts on ion 
pumps will not be discussed any further. 
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2.2 Effects on the Sarcoplasmic Reticulum 
2.2.1 Effects on Skeletal Muscle SR 
Doxorubicin opens Ca2+ channels in the SR's terminal cisternae and causes 
Ca2+release through the RyR. Doxorubicin also affects Ca2+ uptake by termi-
nal cisternae regions of the SR. Active Ca2+ uptake into terminal cisternae SR 
vesicles is inhibited by doxorubicin (IC50 = 0.5 µM) [120]. Ca2+ uptake by the 
longitudinal sections of SR is not affected. Ca2+ uptake is defined as the net dif-
ference between Ca2+ influx (mediated by ATP-driven pumps) and Ca2+ effiux 
(mainly through Ca2+ channels). Zorzato et al. showed that the Ca2+ pump in 
both longitudinal as well as terminal cisternae regions of the SR was not affected 
by doxorubicin [120]. Furthermore, the doxorubicin effect on Ca2+ uptake could 
be blocked by ruthenium red, a known antagonist of Ca 2+ release. The change in 
Ca2+ uptake therefore seems to be due to the change in the effiux mechanisms. Ex-
periments with Ca 2+ loaded SR vesicles using radiolabeled 45Ca 2+ directly showed 
that doxorubicin greatly increases Ca 2+ effiux from terminal cisternae SR. 
Abramson et al. showed that anthraquinones directly interact with the protein 
complex by sensitizing the [3H]ryanodine-binding site to activation by Ca2+ [1]. 
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Figure 12: Doxorubicin dependence of Ryanodine Binding (A) and Ca2+ depen-
dence of Ryanodine Binding (BJ. A: [3H)ryanodine-binding assay carried out in 
regular assay buffer without MgC12 • Incubation: 3 hours as 37°C. Nonspecific 
binding determined with 400-fold excess of cold ryanodine, subtracted to obtain 
specific binding. B: [3 H]ryanodine-binding assay carried out in regular assay buffer 
as described in section 3.2.2 in the presence of 1 mM MgC12 . Incubation: 3 hours 
at 37°C. Nonspecific binding which was determined with a 400-fold excess of cold 
ryanodine was subtracted for specific binding. kd{Ca2+) for the control: 2.18 µM, 
for the activation curve with 10 µM doxorubicin: 1.01 µM. 
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that doxorubicin induced Ca2+ release is inhibited by Mg2+ and is stimulated by 
adenine nucleotides. 
The interactions between the Ca2+ release channel and doxorubicin resemble 
the interactions between caffeine and the Ca2+ release channel. Similarities with 
the effects of caffeine, a drug that acts directly on SR, suggests that doxorubicin 
and caffeine mobilize the same pool of Ca2+ in terminal cisternae [120). How-
ever, comparison of caffeine induced contractions before and after exposure to 
anthraquinone shows that the anthraquinone interacts with a site distinct from 
the caffeine site [82]. Unlike caffeine, doxorubicin not only sensitizes the channel 
to Ca2+ activation, but it also enhances ryanodip.e receptor occupancy (Fig. 12A). 
Overall, anthraquinones are much more potent stimulators of Ca2+ release from 
SR vesicles than caffeine. 
2.2.2 Effects on Cardiac Muscle SR 
Kim et al. were the first ones to directly measure the effects of doxorubicin on 
Ca2+ fluxes in cardiac SR [57]. Their findings show that also cardiac SR shows a 
similar sensitivity to activation by caffeine and doxorubicin as does skeletal muscle 
SR, the sensitivity of these two preparations to activation and inhibition by Ca2+ 
is markedly different. Maximal activation of doxorubicin or caffeine induced Ca2+ 
release in cardiac muscle occured at Ca2+ concentrations around 0.2 µM, whereas 
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micromolar concentrations of Ca2+ inhibited Ca2+ release. This is in contrast 
with findings on skeletal muscle SR in which maximal Ca 2+ release is observed 
at micromolar concentrations of Ca 2+. Kim et al. conclude that the molecular 
mechanism of Ca2+ release in cardiac SR differs from that in skeletal SR. 
2.2.3 Summary 
Experiments presented in this study were carried out with skeletal muscle SR. 
This preparation is well understood and easily available. As previously described, 
the effect of doxorubicin on skeletal and cardiac SR are similar. In this study it is 
shown that ADR-925 protects skeletal muscle SR from modification by doxorubicin. 
Further studies using cardiac SR will be necessary to determine if the cardiac SR 
release channel is similary protected from doxorubicin modification by ADR-925. 
2.3 Dexrazoxane 
The singular success of doxorubicin on the one-hand and the limitations in clinical 
use on the other have stimulated investigations for a "better doxorubicin" [116]. 
Besides ongoing research for new anthracycline analogs and modifications of doxo-
rubicin itself, one major research pathway is the administration of agents that 
protect against doxorubicin cardiotoxicity. 
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Starting in the 1960s a series of derivatives of ethylenediamine tetra-acetic acid 
(EDTA) were synthesized and tested for antitumor activity [116]. One of the 
compounds which has undergone the most evaluation is dexrazoxane ( cardioxane, 
ICRF-187, ADR-529). Dexrazoxane is a more water soluble EDTA analog and was 
proven to prevent anthracycline cardiotoxicity without compromising the drugs 
anti tumor efficacy (92]. 
After over 20 years of ongoing research, dexrazoxane was approved in 1995 by 
the US. Food and Drug Administration (FDA) for preventing cardiotoxicity that 
occurs in women receiving doxorubicin for metastatic breast cancer, who have 
already received a cumulative doxorubicin dose of 2:: 300 mg/m2 [63]. 
Dexrazoxane itself is most likely not the active drug preventing cardiotoxicity. 
Vile et al. showed evidence that dexrazoxane is intracellulary converted to the fully 
open ring hydrolysis product ICRF-198 (ADR-925) [66] [112). This is thought to 
occur in a two-step process with one-ring open intermediates, as shown in Fig. 13. 
The hypothesis, that the metabolite of dexrazoxane is the actual cardioprotective 
agent, is supported by multiple research groups and publications [37] [38] [43] [63) 
[112). 
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Figure 13: Structures of 
dexrazoxane (A, ICRF-187), 
its one-ring open hydrolysis in-
termediates B and C, and its 
two-ring open strongly metal 
ion binding product D (ADR-
925). Reproduced from [66]. 
The molecular structure of ADR-925 (ICRF-198, dl-NN'-dicarboxamidomethyl-
NN'-dicarboxymethyl-1, 2-diaminopropane), the hydrolysis product of dexrazox-
ane, is shown in Fig. 13. 
Dexrazoxane is able to diffuse through cell membranes passively and is hy-
drolyzed to ADR-925 internally as well as externally7. ADR-925 itself is too polar 
to be taken up by the cell directly. The kinetics of the hydrolysis were determined 
by Hasinoff [37]: dexrazoxane decays in a physiological environment with a half-
life of 9.3 hours. The intermediate B in Fig. 13 was observed to be created first, 
at about twice the rate of which intermediate C is produced. The final product, 
ADR-925 is produced with a half-life of 23.0 hours. 
7 under physiological conditions. Dexrazoxane is not hydrolyzed in H20. 
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Buss et al. showed that ferrous ion strongly promotes the ring opening of the 
hydrolysis intermediates (B and C in Fig. 13) [17). In the same publication they 
suggest that the intermediates chelate free iron or displace Fe2+ and Fe3+ from their 
doxorubicin complexes, and then undergo rapid conversions to Fe2+ -ADR-925. 
Z.-X. Huang et al. showed that ADR-925 binds Fe2+ with high affinity [42). 
The stability constants for ADR-925 and EGTA are shown in table 2. In ryanodine 
binding assays which are stronlgy Ca2+ dependent, experiments carried out with 
ADR-925 require the addition of appropriate amounts of Ca2+ to maintain the 
[Carree] within the assay. [Carree] were assayed using a Ca2+-selective electrode (see 
section 3.2.l on page 63). 
2.5 Proposed Mechanisms of Cardioprotection 
The mechanism by which dexrazoxane/ ADR-925 decreases doxorubicin cardiotox-
icity is very controversial. Dexrazoxane was shown not to perturb doxorubicin's 
distribution, metabolism, or excretion in the body [41]. Thus these mechanisms 
can be eliminated a priori. 
Every suggested mechanism of cardioprotection seems to be based on the free 
radical hypothesis of doxorubicin's cardiotoxicity and the strong metal ion chelat-
ing ability of ADR-925. 
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L = EGTA L = ADR-925 pqr 
log({3pqr) log({3pqr) 
M =Proton 
101 9.46 7.551 
102 18.24 11.348 
103 20.89 13.067 
104 22.89 -
M = Calcium(II) 
110 10.97 6.887 
111 16.33 9.693 
210 - 8.183 
M = Magnesium(II) 
110 5.21 5.081 
111 8.61 8.896 
210 - 6.912 
M = lron(II) 
110 11.81 9.993 
111 - 12.208 
r.l _ [LeM9 Hr] 
fJpqr - (L]P(M]9(H]r 
Table 2: Formation constants for EGTA and ADR-925 at 37°C. The equation for 
the stability constants {3pqr is shown in the last row. M stands for the metal, L 
symbolizes the ligand, and II represents protons. The bracket symbol indicates 
the molar concentration of the specified compound. EGTA data based on [94], 
ADR-925 data from [42]. 
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2.5.1 Cardioprotection by Ion Chelation 
The ion chelating hypothesis is based on the effects of the hydrolyzed form of 
dexrazoxane, ADR-925. ADR-925 is a potent intracellular chelator of heavy met-
als. According to this theory, dexrazoxane crosses readily into the myocardial cell, 
where it is rapidly (half-time: 23 hours) hydrolyzed to ADR-925 (37]. ADR-925 
then binds to intracellular iron, inhibiting the conversion of superoxide anions and 
H20 2 to the extremely toxic hydroxyl radicals. ADR-925 was even shown to be 
able to remove iron from ferritin (39], which was demonstrated to be another iron 
source for doxorubicin (24] (see section 2.1.1 on page 43). ADR-925 also suppos-
edly prevents the recycling of ferrous ion back to ferric ion for use by superoxide 
anion radicals. 
This hypothesis is questioned by different research groups. Thomas et al. 
showed that ADR-925 in combination with doxorubicin actually promotes hy-
droxyl radical production via the Fenton reaction8 , and therefore cannot protect 
against intracellular OH production [106]. Hasinoff presents further evidence that 
the Fe2+ -ADR-925 complex indeed produces hydroxyl radicals promoted by the 
NADPH-cytochrome-P450 reductase [38]. However, in the same article he postu-
lates models in which the hydroxyl radical production of the Fe2+ -ADR-925 com-
plex might be less harmful than radicals generated by a iron-doxorubicin complex. 
8 Fenton reaction: Fe2+ + H202 ---t Fe3+ +OH- +UH 
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Hasinoff shows that hydroxyl radical production by the iron-ADR-925 complex is 
much slower than by the iron-doxorubicin complex. Furthermore he speculates 
that the hydroxyl radical production by Fe2+ -ADR-925 might take place at a dis-
tinct, less harmful location than the one by the iron-doxorubicin complex. 
Sobol et al. pointed out that ADR-925 might very well complex the free iron 
and even remove Fe3+ from the adriamycin-Fe3+ complex, but remarks that the 
iron supply in vivo is plentiful, so that this might not be the cardioprotective 
mechanism [98]. Furthermore, due to very high complex formation constants, 
doxorubicin might replace iron from iron-proteins like ferritin. 
Sobol et al. determined that dexrazoxane could form a ternary complex with an 
existing anthracycline-iron complex in an isolated aqueous environment [98]. This 
was the result of computational simulations of the ternary complex and FT-NMR 
spectroscopy. 
2.5.2 Cardioprotection by Increased Glutathione Levels 
It is known that glutathione acts as the major intracellular reducing agent and 
as a potent free radical scavenger. It has been suggested that dexrazoxane acts 
as a cardioprotectant by scavenging free radicals and hence preventing loss of 
reduced intracellular GSH. However, Alderton et al. disproved this model [7]. 
After treatment of mice with doxorubicin, dexrazoxane or the combination of both 
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drugs, no significant difference in reduced glutathione levels could be observed. 
Alderton et al. also showed that in spite of no difference in reduced glutathione 
levels, electron micrographs of mitochondria and myofibrils demonstrated that 
dexrazoxane is a potent cardiprotectant. 
2.5.3 Summary 
Dexrazoxane appears to act as a cardioprotectant by scavenging free radicals. Sev-
eral different reaction mechanisms have been proposed, however no clear pciture 
describing the mode of action of this drug has evolved. Further research will be 
necessary to bring the biophysical/ chemical understanding to the level of the em-
pirical/ clinical research. Once the mechanism of cardioprotection is understood, a 
directed approach to rational drug design should lead to improvements in protocols 
utilizing doxorubicin therapy. 
2.6 Medical Application as a Cardioprotective 
This section on the medical application of dexrazoxane is not intended to cover 
clinical studies and strategies. Its purpose is to give the necessary background 
for the usage of the drug in the described experiments. Important numbers in-
clude physiological concentration and the time-scale of doxorubicin/ dexrazoxane 
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therapy. For a medical review on dexrazoxane cytoprotection see reviews [75] and 
[92]. 
Clinical tests showed that dexrazoxane administration 30 minutes before the 
doxorubicin treatment produced the best cardioprotective results [41]. This effect 
could be further supported by similar results in experiments done on mice [10]. 
The reported ratio of dexrazoxane to doxorubicin varies between 10: 1 and 30: 1 
(ratio by weight) [41]. For the usual doxorubicin treatment this results in an 
average dose D of 600 mg/m2 body surface. Due to a lack of references, a rough 
molar concentration of dexrazoxane/ ADR-925 inside the body was estimated as 
follows: The assumption of an equal distribution of the drug throughout a m = 
80 kg body with a surface A= 2 m2 and an average density p of roughly 1 kg/dm3 
yields an overall concentration of 
c= p·m 
where Mis the molecular weight of ADR-925 (M = 304 g/mol). Most experiments 
presented in this study that involve ADR-925 or dexrazoxane were performed with 
a drug concentration of either 60 µM in order to be close to physiological concen-
tration, or at 300 µM for an increased visibility of the effect. 
Chapter 3 
Materials and Methods 
3.1 Materials 
3.1.1 Chemicals 
Doxorubicin hydrochloride with purity approximately 98% was purchased from 
Sigma, St. Louis, Missouri. The compound was dissolved in double distilled H2 0 
and stored at -18°C. Dexraxozane (ADR-529) was a gift from Adria Laboratories, 
Columbus, Ohio. Dexrazoxane was freshly prepared in ddH20 for every experiment 
and kept on ice throughout the experiment to prevent hydrolysis to ADR-925. 
ADR-925 was provided as a gift by Adria Laboratories. ADR-925 was dissolved in 
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ddH20 in small aliquots and stored in the freezer at - l8°C. An ADR-925 stock 
was never used longer than 4 weeks. 
[3H]ryanodine was obtained from E. I. du Pont de Nemours and Co., Wilm-
ington, DE and stored in the freezer at -18°C. Calcium chloride dihydrate was 
purchased from Mallinckrodt, St Louis, Missouri. Ethyleneglycol-bis-(,Baminoethyl 
ether)N,N,N',N'-tetraacetic acid (EGTA) and all other reagents were purchased 
from Sigma, and stored at room temperature. 
3.1.2 SR-Preparation 
The sarcoplasmic reticulum vesicles used in all experiments were prepared from 
New Zealand White rabbit hind leg and back white skeletal muscle according to 
MacLennan [65]: After removing the fat and connective tissue, the muscles were 
placed in buffer A 1 and quickly blended. The muscles were homogenized in the 
blender alternating low and high speed2 • The resulting solution was centrifuged 
at 1600 g for 10 minutes. The supernatant was filtered through four layers of 
cheesecloth and adjusted to pH 7.4 with dry imidazole. The filtrate was then cen-
trifuged at 10,000 g for 14 minutes. The supernatant was poured through 4 layers 
of fresh cheesecloth. The brown pellet composed of mitochondria was discarded. 
1 120 mM NaCl, 10 mM Imidazole, 100 µM DTT and 200 mg/L Leupeptin; pH 7.4 
2 low speed for 15 seconds, high speed for 60 seconds. Cycle repeated 5 times with 30 second 
breaks between the cycles 
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The resulting supernatant was then spun in an ultracentrifuge at 44,000 g for 70 
minutes. The supernatant was discarded. The white pellet was homogenized with 
a glass homogenizer and then resuspended at approximately 10 mg/ml in buffer 
A. This solution was then centrifuged at 7500 g for 10 min. The resulting myosin 
pellet was discarded and the supernatant was centrifuged at 78,000 g for 30 min-
utes. The SR pellet from this last spin was suspended into buffer B3 • The SR was 
frozen and stored in liquid nitrogen. The protein concentration was determined by 
spectroscopy as described in [56]. 
3.2 Methods 
3.2.1 Determination of Free Calcium Concentration 
As described before, ADR-925 binds Fe2+ with high affinity (section 2.4). For 
its use in strongly Ca2+ dependent assays, the addition of appropriate amounts 
of Ca2+ was required to maintain the [Carree] within the assay. For the theoret-
ical determination of the amount of Ca2+ that had to be added to the system a 
computer program was created. The program is based on the formation constants 
of ADR-925 published in reference [42]. The software can handle the presence 
of other metals (Mg2+ and Fe2+) as well as EGTA. EGTA was used as a Ca2+ 
3 100 mM KCI, 20 mM Hepes; pH 7.0 
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chelator to adjust Ca 2+ levels in control experiments. However, for most of the 
experiments the calculated Ca 2+ concentrations were checked by potentiometric 
measurements with the Ca2+ selective electrode (see section 3.2.3 on page 69). 
The calculations are very sensitive to the initial Ca2+ concentrations before the 
addition of ADR-925 or EGTA. In cases where the initial Ca2+ contents could 
be determined precisely the program predicted free calcium concentrations after 
ADR-925 or EGTA additions with an error < 10%. A detailed description of the 
program and the algorithms used can be found in Appendix 5 (page 99). 
3.2.2 Ryanodine Binding Assays 
Ryanodine is a neutral alkaloid isolated from the stems of the plant Ryania speciosa 
Vahl. It is believed that the plant uses this substance to protect itself against 
insects. Taken up by an animal, ryanodine causes an irreversible contraction of 
skeletal and cardiac muscle by locking the Ca2+ channels in an open state. 
Ryanodine increases the efflux of Ca2+ from heavy SR vesicles of skeletal mus-
cle. It also activates Ca2+-transport ATPase and stimulates the Ca2+ uptake by 
junctional SR vesicles up to 10-fold at high ryanodine concentrations [29]. 
Furthermore tritium labeled Ryanodine ([3 H]ryanodine) binding and the Ca2+ 
induced Ca2+-release share the following characteristics: localization in the ter-
minal cisternae of the SR, Ca2+ dependency (stimulated binding/release at Ca2+ 
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concentrations> 1 µM; inhibited binding/release at Ca2+ concentrations> 1 mM), 
inhibition by Mg2+ and ruthenium red, and modulation by adenine nucleotides [29]. 
Pessah et al. and others concluded that [3H]ryanodine binds to the open state 
of the Ca 2+ release channel. This makes it a powerful biochemical probe of the 
Ca2+ release mechanism. 
[3H]ryanodine binds with a nanomolar affinity to a single class of receptors in 
the SR. [3H]ryanodine binding is a linear function of protein concentration. It is 
influenced by several factors, such as the presence of modulators of Ca2+ release 
(e.g., Ca2+, Mg2+, caffeine, and adenine nucleotides [82]), ionic strength, pH and 
temperature. The binding of [3H]ryanodine is sensitive to brief periods at elevated 
temperature, i.e., partial and complete loss of binding activity after incubation at 
45°C and 50°C, respectively, for 10 min. 
[3H]ryanodine binding was shown to be optimal at 100-1000 µM Ca2+. Binding 
decreased at higher concentrations ( > 2 mM) The kd (the Ca 2+ concentration for 
one-half of optimal binding) was determined to be 20 µM. 
Mg2+ at 1 mM inhibits radioligand binding to the soluble receptor at all Ca2+ 
concentrations. [3 H]ryanodine binding is stimulated by 1 mM cAMP, even in the 
presence of 1 mM Mg2+. In contrast, 1 mM cGMP is inhibitory at Ca2+ concen-
- trations above 30 µM [29]. 
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In addition to being able to examine changes in equilibrium binding of ryan-
odine, valuable information can be obtained by measuring changes in the kinet-
ics of ryanodine binding in the presence of these activators and inhibitors. The 
dissociation rate of ryanodine is hardly affected by Mg2+, caffeine, AMP-PNP, 
AMP-PCP or high Ca2+, EGTA or NaCl levels. However, high concentrations 
of ruthenium red and unlabeled ryanodine slows down the rate of dissociation of 
bound [3 H]ryanodine. AMP-PNP and AMP-PCP increase the rate of association 
of [3H]ryanodine. Both high ionic strength (NaCl or KCl) and caffeine increase 
the rate of association of [3H]ryanodine to its receptor site. Ruthenium red and 
millimolar Mg2+ decrease the rate of association [21]. A major part of this thesis 
examines the effects of ADR-925 and dexrazoxane on the kinetics of [3H]ryanodine 
binding. 
On (3H]ryanodine binding assays, the method described in [82] was used. 
Briefly, SR vesicles (0.5 mg/ml) were incubated at 37°C for 3 hours in buffer 
containing 250 mM KCl, 25 mM HEPES, 15 mM NaCl, 14 nM ryanodine and 
1 nM [3H]ryanodine. Pessah et al. determined a half time of 24.8 min for the 
association of [3H]ryanodine with its binding site in buffer4 at 37°C. The bind-
ing saturates after three hours5 . Most binding assays were carried out at a free 
4consisting of 60 µM Ca2+, 10% sucrose, and 40 mM Tris maleate; pH 7.1 
5 See Section 4.5: Time Dependencies (page 87) 
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Ca2+concentration of 65 µM (adjusted with CaCh). Depending on the assay, var-
ious channel modifiers were present during the incubation procedure. For details 
on individual experiments refer to figure captions. 
Assays were quenched by rapid filtration trough Whatman GF /B glass fiber 
filters in a cell harvester (Brandel, Gaithersburg, MD). The filters were rinsed 
three times with 3 ml washing buffer containing 250 mM KCl, 15 mM NaCl, 
20 mM Hepes, and 50 mM CaC12 ; pH 7.1. The filters were placed in scintillation 
vials (polytubes, Fisher), filled with 2.5 ml scintillation cocktail (ICN, CytoScint), 
shaken overnight and counted the following day. 
Non-specific binding was measured in the presence of a 400-fold excess of un-
labeled ryanodine and subtracted from the data prior to the calculation of the 
specific binding per mg SR. 
Hill Analysis of Binding Data 
Dose dependent binding assays were fit to the Hill equation. The Hill equation is 
(for assays with activators, i.e., compounds that increase binding with increasing 
concentration) 
[x]n 
B = Bmax kd + [x]n (3) 
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where Bmax is the maximum binding, [ x] is the concentration of the activator 
or inhibitor, and kd is the apparent affinity of the binding site for the activa-
tor/inhibitor. n is called the apparent Hill coefficient. Experiments with inhibitors 
(i.e., substances that decrease binding) were fit to 
( 
[x]n ) 
B = Bmax 1 - kd + [x]n (4) 
The data were fit by nonlinear regression using the Marquardt-Levenberg algo-
rithm. This algorithm seeks the coefficients of the independent variables ( "x-
values") in a way that the sum of the squared differences between the observed 
and predicted values of the dependent variables ("y-values") are minimized. This 
algorithm was implemented in the graphing software Sigma Plot6 and could be 
applied on graphs easily. 
Using the fit-parameters, the EC50 (in case of activators) or the IC50 (for in-
hibitors) could be calculated from 
EC so 
) = k~!;) (5) 
IC so 
Association Kinetic Experiments 
Assays for the determination of the association kinetics of (3 H]ryanodine with its 
binding site were carried out with two different heat reservoirs (water baths). One 
6Sigma Plot Scientific Graphing Software, Version 2.01 by Jandel Cooperation 
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was set to the desired incubation temperature of 37°C and held stable within a 
range of ±0.5°C by an electronic regulator. The second incubator was held below 
3°C with ice water. The rate of binding of [3H]ryanodine is known to slow down 
about 8 fold at room temperature (20°C) compared to 37°C. A negligible amount 
of binding occurs at 3°C over the time course of these experiments. 
One of the problems with time dependent association experiments is the limited 
lifetime of protein at 37°C. A control experiment (data not shown) demonstrated 
that incubation times longer than 15 hours are not appropriate, because of artifacts 
probably due to protein denaturation. 
3.2.3 Ca2+ selective Potentiometry 
The Ca2+ sensitive Electrode 
Measurements of free calcium concentrations and transport of Ca2+ across SR 
vesicles were performed with a Ca2+ selective electrode. This electrode was made 
by spreading over the end of a graphite rod a PVC membrane, in which a liquid 
ion-exchanger was incorporated. The ion exchanger used was IE200 which was 
purchased from World Precision Instruments (WPI) [9]. 
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The Ca 2+ electrode sets up an electrical potential across a membrane which is 
selective for Ca2+. In the absence of interfering ions, the response of the calcium 
electrode is given by the Nernst equation: 
2.3RT 
E = E0 + ~ log Aca2+ (6) 
where E is the measured potential, E0 is a constant including effects of the reference 
electrode, R is the gas constant, T is the temperature, F is the Faraday constant 
and n is the charge on the ion being measured (2 in the case of Ca2+). Aca2+ is 
the calcium activity. 2.3RT /nF is called the Nernst factor and has a theoretical 
value of 29.58 m V for the calcium ion at 25°C. 
The experimental setup includes the sensing electrode, a reference electrode 
and a pH meter. The reference electrode used in our setup is a porous glass 
electrode which is saturated with KCl (3M KCl). For the visualization of the data 
a recorder is connected to the pH meter. For long-time data acquisition and easy 
calibration/transformation, the data are digitized and processed using an IBM XT 
computer. Experiments at different temperatures could be carried out with an 
electronically regulated water bath. 
Data Acquisition 
Prior to every experiment the Ca2+ selective electrode needed to be calibrated in 
the specific buffer that was going to be used in the experiment. Transport assays 
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were performed in a buffer containing 100 mM KCl, 20 mM HEPES, 1 mM MgC12 
at pH 7.0. In cases, where the electrode was used for the determination of free 
calcium concentrations, it was calibrated in the buffer that was used for the specific 
solution of interest. The recalibration for different kinds of buffer was necessary, 
because the Ca2+ selective electrode had minor sensitivity for other ions (mainly 
Mg2+) and reacted differently on buffers with distinct salt concentrations. The 
ionic strength of the solution influenced the sensitivity of the electrode because of 
ionic shielding. 
According to the Nernst equation (6) the relationship between the measured 
electrical potential and the calcium concentration is logarithmic. Linear regression 
of the calibration data in a voltage (V) versus log[Carree] diagram yields slope and 
intercept that can then be used to convert the measured voltage to [Carree]. As 
one can see in Nernst 's equation, the slope of the regression is proportional to the 
absolute temperature T. Experiments at different temperatures therefore required 
a recalibration of the electrode. For a buffer at 20°C with low ionic strength the 
calibration of the electrode used for our experiments yielded a slope close to the 
theoretical value of 29 m V. 
Once calibrated, the system with the connected PC could be used for direct 
Ca2+ concentration readings. Another benefit of the use of a personal computer 
was the ability to monitor and store transient processes. The sampling rate for 
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digitized data on the PC was 10 samples per second, which was adequate for the 
observed processes. 
Transport Assays 
Ca2+ fluxes were monitored with the Ca2+ selective electrode. Transport assays 
were carried out in 3 ml of buffer with 100 mM KCl, 20 mM HEPES, 1 mM 
MgC12 at pH 7.0. During the experiment, the extravesicular Ca
2+ concentration 
was monitored on an x-y recorder as well as the on the connected PC. After the 
addition of 20 µM CaCh to the buffer, 0.2 mg SR per ml buffer was added. The 
SR usually introduced another 2 to 3 µM Ca2+ to the buffer. After equilibration 
0.5 mM MgATP were added to initiate Ca2+ uptake into the SR vesicles. After 
complete uptake the calcium concentration remaining in the buffer was ~ 1.5 µM. 
At this point the drug(s) of interest were added to initiate Ca2+ release. Ca2+ 
efflux rates were determined from the maximal slope of the extra vesicular Ca 2+ 
versus time. For this purpose the digitized recorder data on the PC was of great 
help. A graphed sample data file with linear regression line is shown in Fig. 14. At 
the end of each experiment the Ca2+ ionophore A23187 was added to the solution 
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Figure 14: Sample recorder read-
ing of sample Ca2+efflux assay. The 
slope of linear regression is the efflux 
rate. The huge peak at t = 14s is due 
to the injection of doxorubicin (the 
concentration of doxorubicin in this 
experiment was 3.3 µM) 
Chapter 4 
Results 
4.1 Ca2+ EfHux Assays 
4.1.1 Effects of Dexrazoxane on Doxorubicin Induced 
Ca2+ Release 
Doxorubicin induced Ca 2+ efflux from actively loaded SR vesicles was measured 
in the presence of different concentrations of dexrazoxane. These measurements 
were carried out with a Ca2+ selective electrode as described in section 3.2.3. 
Preliminary experiments were performed to ensure that the Ca 2+ selective electrode 
was properly calibrated and exhibited a sufficiently fast response time to changes in 
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the free Ca 2+ concentration. A sample recorder reading of this type of measurement 
was shown in section 3.2.3 (Fig. 14). 
SR vesicles were suspended in transport buffer as described in Materials and 
Methods, section 3.2.3. After the system was stabilized, Ca2+ uptake was initiated 
by the addition 0.5 mM MgATP. Within minutes, Ca2+ was taken up by the SR 
lowering the extravesicular free Ca2+ concentration to approximately 1.5 µM. At 
this point, the specific concentrations of dexrazoxane were added and allowed to 
stir for about one minute. Ca2+ release was initiated by the addition of 10 µM 
doxorubicin. The efflux rate, normalized per mg SR, was determined from the 
digitized data as described in Materials and Methods. The results of these mea-
surements are shown in Fig. 15. The concentrations of dexrazoxane used in these 
experiments exceeded the range in which it has been used in medical applications. 
According to previous publications [41], dexrazoxane to doxorubicin ratios ranging 
from 10:1 up to 30:1 have been used in medical applications (see section 2.6). 
As shown in Fig. 15, doxorubicin induced Ca2+ efflux was not affected by dexra-
zoxane. The fluctuations in the maximal Ca2+ release rate for different dexrazox-
ane concentrations is most likely due to uncertainties in the determination of the 
maximum slope of Ca2+ release. In addition, slightly different amounts of Ca2+ 
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Figure 15: Doxorubicin induced Ca2+ effiux as a function of dexrazoxane concen-
tration. SR vesicles (0.2 mg/ml) were suspended in 100 mM KCl, 1 mM MgC12 , 
10 µM CaC12 , 20 mM HEPES; pH 7.0, at a protein concentration of 0.2 mg/ml. 
Ca2+ uptake was initiated by the addition of 0.5 mM MgATP. Different concentra-
tions of dexrazoxane were added after Ca2+ uptake was complete and 60 sec prior 
to the addition of doxorubicin (10 µM). Prior to the addition of doxorubicin, the 
free Ca2+ was adjusted to l.5µM (by addition of another 1±0.3 µM CaC12 ). V 
was measured from the maximum slope of the Ca 2+ concentration versus time and 
normalized per mg protein. 
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4.1.2 Limitations of Transport Assays in Experiments In-
volving Strong Ca2+ Chelators 
The Ca2+ effiux assay described in the previous section was also used to examine 
the effects of ADR-925 on doxorubicin induced Ca 2+ release. However, due to its 
ability to chelate Ca2+, ADR-925 itself affected the response of the Ca2+ selective 
electrode. Following Ca2+ effiux from the SR, a large fraction of the released 
Ca2+ bound to ADR-925 and was therefore not detected by the electrode. The 
computer program WORSE (described in section 3.2.1) was used to transform the 
acquired concentration of free Ca 2+ at every timepoint in the experiment to the 
total concentration of Ca2+ present outside the SR vesicles. 
Analysis of this final data (not shown) revealed a number of problems associated 
with this method. First, minor uncertainties in the initial Ca 2+ concentration, 
before the addition of doxorubicin, translate to major fluctuations in the effiux 
rate. This is due to the fact that the transformation of Cair!e to Ca~tiai is not 
linear. The calculated rate of Ca2+ release is therefore a function of the initial Ca2+ 
concentration. Second, with increasing concentrations of ADR-925 the amount of 
Ca 2+ release observed gets smaller (more released Ca 2+ is chelated, and the change 
in the free Ca2+ concentration becomes smaller). For ADR-925 concentrations 
above 80 µM, signal acquisition became impossible because of the limited resolution 
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of the digitizer. And, finally, the transformation of the acquired free concentrations 
to total concentrations increased the noise in the signal dramatically. Whereas the 
signal itself got smaller for increased ADR-925 concentrations, the noise stayed 
the same. Therefore the signal to noise ratio decreased for increasing AD R-925 
concentrations. In summary, ion selective potentiometry is not an appropriate 
method for the determination of Ca2+ efflux from SR vesicles in the presence of 
ADR-925. In order to study the effects of ADR-925 on the calcium release channel, 
other experimental methods and procedures must be utilized. 
4.2 Effects of ADR-925 and Dexrazoxane on 
Ryanodine Binding 
The ability of dexrazoxane and ADR-925 to modify high affinity [3H]ryanodine 
binding to its receptor were examined in Fig. 16. SR vesicles were suspended in the 
binding buffer as described in Materials and Methods, section 3.2.2. Dexrazoxane 
stock solutions were prepared fresh before each experiment at a concentration of 
100 mM. ADR-925 stock solution was prepared in water at a concentration of 
100 mM. The stock solutions were then diluted 1:10 with ddH20 several times and 
stored on ice. To adjust free Ca2+ levels in the presence of ADR-925, appropriate 
CaCb aliquots were added, as determined by the software program WORSE. The 
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free Ca2+ levels for each individual sample were verified with the Ca2+ selective 
electrode and were found to be within 10% of their expected value. 
The data were fit to the Hill equation as described in Materials and Methods, 
section 3.2.2. The IC50 (concentration of the titrated compound that yields 1/2 of 
maximum binding) for ADR-925 in this experiment was determined to be 90 µM. 
The calculated IC50 for dexrazoxane was 3. 7 mM. 
Fig. 16 shows that ADR-925 inhibits high affinity ryanodine binding. Dexra-
zoxane also seems to inhibit binding, but only at very high concentrations of the 
drug. The IC50 for dexrazoxane is about 40 times the IC50 of ADR-925. 
4.3 Doxorubicin Dependence of Ryanodine 
Binding: Effect of ADR-925 on Doxorubi-
cin Dependence 
Fig. 17 shows the doxorubicin dependence of ryanodine binding in the presence and 
absence of 300 µM ADR. The assay was carried out at a free calcium concentration 
of 7.5 µM, in the presence of 1 mM MgC12 • Abramson et al. have previously 
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Figure 16: Effect of ADR-925 and dexrazoxane on ryanodine binding. 
[3H]ryanodine binding assay carried out as described in Materials and Methods, 
section 3.2.2. The buffer contained 1 mM free Mg2+ and 7 .5 µM free Ca 2+. The 
concentrations of free Mg2+ and Ca2+ were held constant by appropriate additions 
of MgCl2 and CaCh, respectively. The concentration of free Ca 2+ for every data 
point was double checked by potentiometric Ca~r!e determinations as described in 
Materials and Methods, section 3.2.1, and was found to be within 10% of the cal-
culated value. The samples were incubated at 37°C for 4.5 hours. Nonspecific 
binding was determined with a 400-fold excess of ryanodine. Assays were termi-
nated by rapid filtration through Whatman GF /B glass fiber filters as des_cribed 
in section 3.2.2. The data for ADR-925 are an average of two experiments carried 
out in duplicate; the data for dexrazoxane are the average of duplicates of one ex-
periment. The data were fit to a modified Hill equation for inhibitors as described 
in section 3.2.2. For the fit parameters see text. 
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presence of inhibitors like Mg2+ [1 ]. Specific ryanodine binding was monitored over 
the range of 0 to 500 µM doxorubicin. 
In this experiment, doxorubicin activation of ryanodine binding did not reach 
saturation in the observed concentration range. However, 300 µM ADR-925 was 
an effective inhibitor of ryanodine binding. The amount of inhibition by ADR-925 
appears to be independent of the doxorubicin concentration. The data were fit to 
the modified Hill equation (Eqn. (3) plus a constant offset representing binding at 
0 µM doxorubicin). 
4.4 Effect of ADR-925 on the Calcium Activa-
tion of Ryanodine Binding 
High affinity ryanodine binding to the SR is strongly Ca2+ dependent [82). The 
effects of ADR-925 on the calcium activation of ryanodine binding were studied. 
The free Ca2+ concentration in this study was varied by various additions of either 
EGTA or CaCh as calculated by WORSE. The absolute values of [Carree] were 
verified by measurements with the Ca 2+ electrode, where applicable (usable range 
of the electrode: ~ 1.5 to 100 uM). The free Ca2+ concentrations for corresponding 
data points outside of this range were brought to the same level by additions of 
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Figure 17: Effects of 300 µM ADR-925 on the doxorubicin dependence of ryanodine 
binding. SR vesicles (0.5 mg/ml) were incubated at 37°C for 3 hours, in a buffer 
containing 250 mM KCl, 15 mM NaCl, 20 mM Hepes, 1 mM MgC12 , 14 nM 
ryanodine and 1 nM [3 H]ryanodine. [Carree] was adjusted to 7.5 µM for both the 
control and the ADR-925 treated samples. Non-specific binding was determined 
with a 400-fold excess of cold ryanodine. The data were fit to a modified Hill 
equation for activators including an additive constant representing the binding at 
0 µM doxorubicin. 
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EGTA and CaCh so that the same m V reading on the electrode was obtained for 
all four samples. 
Fig. 18 shows the calcium activation of ryanodine binding for SR vesicles incu-
bated in a buffer containing 250 mM KCl, 15 mM NaCl, 20 mM HEPES, 14 nM 
cold ryanodine and 1 nM [3 H]ryanodine. After 3 hours of incubation at 37°C the 
experiment was quenched by rapid filtration as described in section 3.2.2. 
High affinity ryanodine binding increases with Ca2+ concentration until sat-
uration is reached at [Carree] = 50 µM. Binding decreases for Ca 2+ levels above 
100 µM. 10 µM doxorubicin increases ryanodine binding compared to the con-
trol from approximately 2.8 pmol/mg to approximately 3.5 pmol/mg. ADR-925 
(300 µM) did not significantly change the Bmax· However, the Ca2+ activation was 
shifted to the right, towards higher [Carree] levels. The EC50 (free Ca
2+ concen-
tration that yields 1 /2 maximum binding) for the experiment without doxorubicin 
was shifted from 0.4 µM to 1.1 µM [Carree]· 
This did not appear to be the case in the presence of doxorubicin ( 10 µM). 
When treated with doxorubicin, the ADR-925 did not shift the Ca2+ activation 
curve. The EC50 was determined to be ~ 0.3 µM in the presence of the an-
thraquinone. However, the Ca2+ activation of ryanodine binding appeared to be 
less steep, when ADR-925 was present. This, indeed, is reflected by the Hill coeffi-
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Figure 18: Effects of doxorubicin and ADR-925 on Ca2+ activation of ryanodine 
binding in the absence of Mg2+. SR vesicles (0.5 mg/ml) were suspended in buffer 
containing 250 mM KCl, 25 mM HEPES, 15 mM NaCl, 14 nM ryanodine and 
1 nM [3 H]ryanodine. The concentration of free Ca2+ was adjusted as described 
in the text. The samples were incubated for 3 hours at 37°C and then filtered as 
described in Materials and Methods. The rising edge of the data were fit to the 
Hill equation. The parameters of the fit are discussed in the text. 
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without ADR-925 were 2.8 and 2.6 (without and with 10 µM doxorubicin, respec-
tively). The experiments with ADR-925 yielded Hill coefficients of 1.3 without 
and with 10 µM doxorubicin. In the absence of Mg2+, ADR-925 decreased the 
degree of positive cooperativity associated with Ca2+ activation of the ryanodine 
receptor. 
The addition of Mg2+ increases the effects of doxorubicin and ADR-925 on 
the Ca2+ activation (Fig. 19). In this figure, doxorubicin increased total binding 
compared to the control. In the presence of 1 mM Mg2+, the Bmax values were gen-
erally lower than in Fig. 18. Doxorubicin was observed to sensitize the receptor to 
activation by Ca2+. This was in agreement with both Fig. 18 as well as previously 
published data by Abramson et al. (1]. ADR-925 did not significantly alter the 
Bmax of high affinity ryanodine binding. The fit parameters from the Hill analysis 
reveal a large increase in the EC50 for titrations in the presence of 300 µM ADR-
925. The EC50 for the experiments without doxorubicin are 1.9 µM and 8.4 µM, 
without and with 300 µM ADR-925, respectively. The activation assays in the 
presence of 10 µM doxorubicin show a shift of the EC50 from 1.0 µM to 3.6 µM 
in the presence of 300 µM ADR-925. The Hill parameters in this experiment do 
not show significant differences for the four titrations. The Hill fit parameters are 
summarized in Table 3. 
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Figure 19: Effects of doxorubicin and ADR-925 on Ca2+ activation of ryanodine 
binding in the presence of 1 mM Mg2+. The experiment is carried out as described 
in Fig. 18 with the addition of 1 mM free Mg2+. 
87 
Bmax kd n EC50 
[(pmol/mg)] [µM] [µM] 
0 µM ADR-925, 0 µM doxorubicin 1.0 2.1 1.1 1.9 
300 µM ADR-925, 0 µM doxorubicin 1.0 10.4 1.1 8.4 
0 µM ADR-925, 10 µM doxorubicin 1.5 1.0 1.1 1.0 
300 µM ADR-925, 10 µM doxorubicin 1.5 3.9 1.1 3.6 
Table 3: Hill parameters for Ca2+ activation assay in the presence of 1 mM 
Mg2+(Fig. 19). 
Double reciprocal analysis of the data reveals that the mechanism by which 
ADR-925 inhibits the binding of [3H]ryanodine is by competing with Ca2+ binding 
to its activation site on the RyR complex (Fig. 20). 
4.5 Ryanodine Association Experiments 
To better describe the interaction between ADR-925 and the ryanodine receptor, 
ryanodine association experiments were conducted. An example of an association 
experiment is shown in Fig. 21. 
Chu et al. showed that Mg2+ slows ryanodine binding to the RyR [21]. The 
same effect can be seen for inhibition of [3H]ryanodine binding by low calcium 
concentrations (data not shown). In the presence of Mg2+, the inhibitor ADR-925 
further slowed the time dependent process of [3H]ryanodine binding (Fig. 21 ). 
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Figure 20: Double reciprocal analysis of ryanodine binding assay carried out in 
assay buffer containing 1 mM Mg2+ (Fig. 19). The linear regressions of 1/B vs. 
1/[Carree] for both sets of experiments, without and with 10 µM doxorubicin, in-
tersect on the y-axes. This suggests that ADR-925 directly competes with Ca2+ 
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Figure 21: Time dependence of ryanodine binding. The assay was the same as 
described above. [Carree] was adjusted to 1.5 µM by additions of 70 µM EGTA for 
the control experiment and 63 µM EGTA for the experiment with 60 µM ADR-
925. After the given time, samples were placed on ice in order to stop incubation. 
After 12 hours the samples were filtered as described in section 3.2.2. The data 
were fit to Eqn. (7) shown in the text. 
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The binding data from this experiment were fit to a first order ligand receptor 
interaction equation: 
B = Bmax ( 1 - e-kobs·t) (7) 
where B is the amount of ryanodine bound at the time t. The fit from Fig. 21 
yielded a kobs = 0.346hr-1 for the control and kobs = 0.133hr-1 in the presence 
of 60 µM ADR-925. Therefore, in the presence of 1 mM Mg2+ and 1.5 µM Ca2+, 
the time required for 1/2 of the maximum binding to occur was 2.0 hours and 
5.2 hours for the control and the experiment with 60 µM ADR-925, respectively. 
Interestingly, both fits reached the same maximal level of binding, approximately 
1.6 pmol/mg. In an experiment carried out over a longer time period than the 
one shown in Fig. 21, it was observed that ryanodine binding becomes unstable 
after incubation for longer than approximately 15 hours (at 37°C). Therefore, 
equilibrium binding for the experiment shown in Fig. 21 is not reached before the 
receptor is damaged. 
4.6 Effects of ADR-925 on the [H202] Depen-
dence of Ryanodine Binding 
As described above it has been reported that doxorubicin in vivo becomes easily 
reduced to the semiquinone, which is oxidized by molecular 0 2 back to doxorubicin. 
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This results in the production of superoxide anion. In the cell, superoxide is readily 
converted to hydrogen peroxide (H20 2). High concentrations of H202 were shown 
to have a potent inhibitory effect on the SR Ca2+ release mechanism [30]. The 
effects of ADR-925 on inhibition of receptor binding by H20 2 were examined in 
Fig. 22. The inhibition of [3H]ryanodine binding by H20 2 was significantly altered 
by 300 µM ADR-925. The IC5o for H20 2 inhibition of binding shifted from 60 µM 
(no ADR-925) to 200 µM ( +300 µM ADR-925). 
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Figure 22: The effect of ADR-925 on the peroxide dependence of ryanodine bind-
ing. The binding assay was performed as described in Materials and Methods, 
(section 3.2.2) at 50 µM [Carree] and various concentrations of H20 2 , in the pres-
ence or absence of ADR-925 (300 µM). In the presence of ADR-925 the free calcium 
was adjusted to 50 µM by the addition of 300 µM CaCb. 
Chapter 5 
Discussion and Conclusion 
In this report, the combined interactions between doxorubicin and dexrazoxane on 
the Ry R/ Ca 2+ release channel have been examined. Dexrazoxane is a compound 
used as a cardioprotectant in doxorubicin cancer treatment. Once administered 
to the body, dexrazoxane is metabolized resulting in the formation of ADR-925. 
Initial experiments in this study have indicated that dexrazoxane has little effect 
on the transport properties of doxorubicin induced Ca2+ efflux from SR vesicles. 
This observation was supported by high affinity ryanodine binding measurements. 
Dexrazoxane had little effect on Ca2+ activated [3H]ryanodine binding. In contrast, 
the dexrazoxane metabolite ADR-925 was shown to directly modulate ryanodine 
binding. ADR-925 appears to alter the sensitivity of the ryanodine receptor to 
Ca2+ activation. It was clearly shown that ADR-925 but not dexrazoxane is the 
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active compound responsible for the alteration of the calcium sensitivity of the 
RyR. Under physiological conditions and in the absence of activators, ADR-925 
(300 µM) increased the EC50 for Ca2+ activation approximately four-fold. Double 
reciprocal analysis of the Ca2+ activation data indicates a competitive interaction 
between Ca2+ activation and ADR-925 inhibition. This suggests that Ca2+ and 
ADR-925 interact with the same site on the RyR. 
Surprisingly, ADR-925 did not reverse doxorubicin stimulated ryanodine bind-
ing. It appears that the inhibitory effect of ADR-925 on the release channel is 
independent of the doxorubicin concentration. Moreover, ADR-925 competitively 
interacts with the Ca2+ activation site of the ryanodine receptor. Abramson et 
al. have previously reported that doxorubicin sensitizes the Ca2+ activation of the 
ryanodine receptor. One possible cardioprotective mechanism of dexrazoxane may 
therefore be the reversal of this effect by ADR-925. 
The effect of ADR-925 on Ca2+ activation of ryanodine binding may underlie 
a deeper physiological significance. Dexrazoxane/ ADR-925 is administered to pa-
tients to combat the deleterious effects of doxorubicin on cardiac muscle. Ca2+ is 
thought to be the chemical trigger of EC coupling in cardiac muscle. Influences 
on Ca2+ induced Ca2+ release will therefore affect the EC coupling mechanism 
directly, and gain increased importance. Yet, it still has to be shown that the 
desensitizing effect of ADR-925 on Ca2+ activation also persists in cardiac muscle. 
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Analysis of the stability constants [42] indicates that ADR-925 has a high 
binding affinity for iron (table 2). As described in section 2 .1.1, iron has been 
speculated to play a primary role in free radical induced cardiotoxicity. However, 
this hypothesis has remained controversial. The significance of iron in cardiotoxic 
and cardioprotecti ve mechanisms was not addressed in this report. The amount of 
iron available in vivo and in the SR preparations shown was not directly measured. 
The cardioprotective mechanism of dexrazoxane is not only due to the strong iron 
chelating action of its metabolite, ADR-925, but also may involve direct, iron-
independent effects on the ryanodine receptor of the sarcoplasmic reticulum. These 
effects may be relevant to disrupting normal Ca 2+ homeostasis in the muscle. 
This laboratory has investigated the role of thiol oxidation in EC coupling 
and SR calcium release. The ability of the cardioprotective drug, ADR-925 to 
protect the release channel from oxidation by H2 0 2 supports the hypothesis that 
the redox state of critical thiols associated with the release channel play a role 
in EC coupling. The demonstrated ability of ADR-925 to protect the RyR from 
inhibition by peroxide suggests a significant role for ADR-925 in the free radical 
hypothesis of cardiotoxicity. H2 0 2 is a reactive byproduct produced during the 
generation of free radicals (Fig. 8). Therefore it is possible that alteration of 
peroxide induced channel inhibition by ADR-925 may play an important role in 
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Figure 23: Example for the effect of dif-
ferent rate constants in a first order lig-
and receptor interaction. 
to determine which mechanisms are directly responsible for dexrazoxane's action in 
the heart. At the present time, too little is known about the interactions of H2 0 2 , 
ADR-925 and the RyR to draw further conclusions. It remains to be determined 
if ADR-925 and H2 0 2 competitively interact with one specific site on the RyR, if 
ADR-925 is shielding the H20 2 sensitive site, or if ADR-925 is modifying H2 0 2 or 
any of the other reactive oxygen intermediates. 
Errors are sometimes introduced when alterations in parameters (i.e., EC50) 
are measured that may be time-dependent. This is demonstrated in Fig. 23. In 
this figure, first order ligand receptor interaction is shown for four different kobs· 
Experiments carried out at earlier time points will yield less ryanodine binding but 
show differences in time kinetics more dramatically than experiments carried out 
closer to saturation. Therefore, the choice of the incubation time for ryanodine 
binding is an important factor in the design of the experiment. 
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A good example of this are the Ca2+ activation assays presented in this thesis. 
In its role as an activator, Ca2+ affects the kinetics of ryanodine binding. The 
absence of the inhibitor, Mg2+ may bring [3H]ryanodine binding kinetics close to 
saturation and therefore mask the effect. This hypothesis is supported by the data 
presented for Ca2+ activation in absence of Mg2+. ADR-925 does not seem to shift 
the Ca 2+ dependence significantly in the presence of doxorubicin, but does affect 
the control. 
The mechanism of interaction between ADR-925 and the ryanodine receptor 
remains unclear. On the surface, at least two obvious possibilities exist which 
might explain this interaction. ADR-925 may inhibit the gating activity of the 
Ca2+ channel directly. This would be reflected in the ability of ADR-925 to de-
crease channel sensitivity to Ca2+ activation, which would result in lowered channel 
open probability. The decreased channel open probability would allosterically hin-
der ryanodine binding. Alternatively, ADR-925 may directly affect the binding 
affinity of the receptor for ryanodine. The ryanodine binding to its site is known 
to be calcium activated. Alterations in the ligand receptor kinetics may not di-
rectly reflect functional changes in the Ca2+ channel but may represent an artifact 
produced by the experimental assay. Either of these mechanisms would reflect 
the observations presented in this thesis. Further investigations using more direct 
assays measuring channel activity may help to resolve this issue. 
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The results of this report may represent the basis of future investigations of 
the effects of ADR-925 on cardiac muscle SR. Single channel experiments should 
help detail changes in the gating characteristics as a result of exposure to ADR-
925. The role of iron in the process of cardiotoxocity and cardioprotection by 
dexrazoxane remains to be determined. This report may represent an important 
first step in understanding the role of the ryanodine receptor in cardiotoxicity and 
the mechanisms of cardioprotection. 
Appendix 
Software Description: WORSE 
The strong metal chelating abilities of ADR-925 required a tool for simple calcu-
lation of free concentrations of various metals in the presence of ADR-925. The 
different computer programs available in our laboratory were not able to include 
ADR-925 in the calculation. The software BAD (Bound And Determined) did 
not allow input of new binding constants for substances not already included; the 
program CALCIUM did allow the input of new data, but could not handle the 
specific types of complexes that ADR-925 forms with metals. ADR-925 can either 
form a complex involving one ADR-925 molecule and one metal ion or two ADR-
925 molecules and one ion. The solution for these problems was the creation of a 
new computer program that could handle the substances used in this investigation. 
WORSE is able to determine the free concentrations of the metals Ca2+, Mg2+ 
and Fe2+ and the ligands EGTA and ADR-925. An additional algorithm allows 
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the determination of a required total concentration to add to a solution to yield a 
given free concentration. 
1. Algorithms 
The flowchart of the program is shown in Fig. 24. The two central computational 
procedures are the determination of the free concentrations, and the modification 
of the total concentrations to yield a desired free concentration for one of the 
substances. 
The algorithm for the determination of the free concentrations is shown in 
Fig. 25. Briefly, the iteration was initialized by setting the free concentrations 
equal to the total concentrations. As a first step in the iteration the free EGTA 
concentration was calculated as a function of the free ion concentrations according 
to the apparent stability constants: 
[EGTAtot] 
[EGTArr •• ] = l + ku [c~~.j + k12 [Mg~£.r+ k13 [Fel~.j 
kij stands for the apparent stability constant for ligand i and metal j. The apparent 
stability constants for EGTA were calculated on the base of equilibrium constants 
~ult· 
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Figure 24: WORSE Flowchart. The 
two basic algorithms "Calculate con-
centrations of free metals and lig-
ands" and "Choose/Modify total con-
centration of metal/ligand to add" are 
shown in detail in Fig. 25 and Fig. 26, 
respectively 
Start 
Set free Cone. 
= total Cone. 
Cale. free [EGTA) as 
a function of 
free Ca, Mg, Fe 
Cale free [ADR-925) as 
a function of 
free Ca, Mg, Fe 
Cale free pons) as 
a function of 
free EGTA, ADR-925 
T 
( Stop ) 
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Figure 25: Flowchart of the algorithm used to 
determine the concentration of free metals and 
ligands 
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given in [94]; the apparent stability constants for ADR-925 originated from (42]. 
A similar equation was used for ADR-925: 
(AD R-925rree] 
(ADR-925totl 
- 1 + k21 [Cair!e] + k21 [ca:r!e]2 + k22 [Mgir!e] + k22 [Mgir!e]2 + k23 [Feir!e] 
k2j is the apparent stability constant for the complexes of ADR-925, that include 
two molecules of ADR-925 and one molecule of metal j. Based on the calculated 
free concentrations for the two ligands, the free concentration of the metals could 
be calculated. 
b = 1 + ki,j [EGTA]free + k2,j [ADR-925]free 
-b + Jb2 + 8k2,j · [ADR-925]free · [Ion]tot 
(Ion)free = 4k2* · · (ADR-925)r ,J ree 
The iteration repeats, using the newly obtained free concentrations. The iteration 
was stopped after the relative change of the free concentration in the last cycle 
was below 0.1 % for every compound. 
The algorithm used for the calculation of the total concentration that yields a 
desired free concentration is shown in Fig. 26. The algorithm chooses a start value 
for the total concentration of the substance that is supposed to be varried. After 
the calculation of the resulting free concentration with the algorithm described 
before, the program adjusts the total concentration accordingly. The iteration 
stops if the yielded free concentration is in the range of 0.1 % of the desired value. 
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old concentration 
[Modifier) adjusted to 
112.way between 
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Figure 26: Flowchart of the algorithm that calculates the total concentration 
needed to yield a desired free concentration for one of the substances. [Modi-
fier] is the total concentration of the substance that is varied in order to adjust the 
desired free concentration 
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Figure 27: WORSE main screen 
2. Usage 
The present version of WORSE was supplied with a user friendly interface for 
Windows® 3.1. The program is started by a double click on the program icon in 
the program manager. The main window appears on the screen (Fig. 27). The 
total concentrations, the temperature and the pH can be entered. The program 
option Calculate free concentrations uses the input values to determine the free 
concentrations. The option Calculate Ligand/Metal to add finds the total con-
centration of the substance entered in Compound to be varied that is needed to 
obtain the free concentration of the substance chosen in Free concentration of. If 
the checkbox Use Temp. Correction is selected, the binding constants for EGTA 
will be corrected for the temperature given in temperature. Due to a lack of the 
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Figure 28: WORSE result screen 
necessary information, the binding constants for ADR-925 can not be corrected for 
temperatures. If the temperature correction is off, the program calculates correct 
results for 37°C. After clicking the calculate button, a separate result window (see 
Fig. 28) will pop up and display the total and free concentrations of the substances 
as well as the concentration of the complexes that emerge. The result screen has 
to be closed before modifications in the main screen are possible. The Quit button 
on the main screen ends the program. 
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